








**ORIGINAL ARTICLE**

# UK guideline for the use of HIV post-exposure prophylaxis 2021

**Fiona Cresswell**<sup>1,2,3</sup>  | **Kaveh Asanati**<sup>4</sup> | **Sanjay Bhagani**<sup>5,6</sup> | **Marta Boffito**<sup>7,8</sup> | **Valerie Delpech**<sup>9</sup>  | **Jayne Ellis**<sup>1,10</sup>  | **Julie Fox**<sup>11,12</sup> | **Linda Furness**<sup>13</sup> | **Margaret Kingston**<sup>14,15,16</sup> | **Massoud Mansouri**<sup>17</sup> | **Amanda Samarawickrama**<sup>18</sup> | **Kat Smithson**<sup>19</sup> | **Alex Sparrowhawk**<sup>20</sup> | **Paul Rafferty**<sup>21,22</sup>  | **Tom Roper**<sup>23</sup> | **Laura Waters**<sup>23</sup>  | **Alison Rodger**<sup>5,6</sup>  | **Nadi Gupta**<sup>24,25</sup> 

<sup>1</sup>Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK

<sup>2</sup>Clinical Research Department, London School of Hygiene and Tropical Medicine, UK

<sup>3</sup>Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

<sup>4</sup>Department of Primary Care and Public Health, School of Public Health, Imperial College, London, UK

<sup>5</sup>Royal Free Hospital, London, UK

<sup>6</sup>Institute for Global Health, University College London, London, UK

<sup>7</sup>Chelsea and Westminster Hospital, London, UK

<sup>8</sup>Imperial College London, London, UK

<sup>9</sup>Department of Epidemiology, Public Health England, London, UK

<sup>10</sup>University College London, Hospitals NHS Foundation Trust, London, UK

<sup>11</sup>HIV Medicine and Clinical Trials, Guy's and St Thomas' Hospital, London, UK

<sup>12</sup>Kings College London, London, UK

<sup>13</sup>Cardiff Royal Infirmary, Cardiff, UK

<sup>14</sup>British Association of Sexual Health and HIV Clinical Effectiveness Group, Macclesfield, UK

<sup>15</sup>Manchester Royal Infirmary, Manchester, UK

<sup>16</sup>Manchester University, Manchester, UK

<sup>17</sup>Occupational Health, School of Medicine, Cardiff University, Cardiff, UK

<sup>18</sup>Sexual Health South West London, London, UK

<sup>19</sup>National AIDS Trust, London, United Kingdom

<sup>20</sup>Terrence Higgins Trust, London, United Kingdom

<sup>21</sup>Belfast Health and Social Care Trust, Belfast, UK

<sup>22</sup>HIV Pharmacy Association Representative, Newcastle upon Tyne, UK

<sup>23</sup>Mortimer Market Centre, London, UK

<sup>24</sup>British HIV Association Guideline Committee, London, UK

<sup>25</sup>Rotherham NHS Foundation Trust, Rotherham, UK

## Correspondence

Dr Fiona Cresswell, University Hospital Sussex, Brighton, UK.

Email: fiona.cresswell@lshtm.ac.uk

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *HIV Medicine* published by John Wiley & Sons Ltd on behalf of British HIV Association

### Abstract

We present the updated British Association for Sexual Health and HIV (BASHH) guidelines for post-exposure prophylaxis (PEP) to HIV following sexual exposures, occupational exposures and other nonoccupational exposures in the community. This serves as an update to the 2015 BASHH guideline on PEP following sexual exposures and the 2008 Expert Advisory Group on AIDS guidelines on HIV PEP. We aim to provide evidence-based guidance on best clinical practice in the provision, monitoring and support of PEP for the prevention of HIV acquisition following sexual, occupational and other nonoccupational exposures in the community. The guideline covers when to prescribe PEP, what antiretroviral agents to use and how to manage PEP. This includes (i) evidence of PEP efficacy; (ii) evidence relating to individual-level efficacy of antiretroviral therapy to prevent the sexual transmission of HIV; (iii) data on the detectable (transmissible) prevalence of HIV in specific populations; (iv) risk of HIV transmission following different types of sexual and occupational exposure; (v) baseline risk assessment; (vi) drug regimens and dosing schedules; (vii) monitoring PEP; (viii) baseline and follow-up blood-borne virus testing; (ix) the role of PEP within broader HIV prevention strategies, for example, HIV pre-exposure prophylaxis (PrEP). The guideline also covers special scenarios such as PEP in pregnancy, breastfeeding and chronic hepatitis B virus infection, and when PEP should be considered in people using HIV PrEP. The guidelines are aimed at clinical professionals directly involved in PEP provision and other stakeholders in the field. A proforma to assist PEP consultations is included. A public consultation process was undertaken prior to finalizing the recommendations.

### New in the 2021 guideline

1. The indications for, and management of, PEP following occupational exposures, specifically sharps (percutaneous) injuries, splash (mucocutaneous) injuries and bites, are covered in this guideline.
2. Indications for PEP following injecting drug use, including sexualized drug use, are included.
3. Where the source is of unknown HIV status, we no longer use the prevalence of HIV within the source population; instead, we use the *prevalence of detectable HIV viraemia* in the source population when determining the HIV transmission risk. This is because the majority of HIV positive people in the UK are aware of their status and are on effective antiretroviral therapy with an undetectable viral load, which we now know prevents onwards transmission.
4. Further evidence of the negligible risk of HIV transmission following human bites is provided as well as the rare scenarios in which PEP could be considered.
5. There has been introduction of a new category of *'PEP generally not recommended'*, which is for exposures where the risk is negligible and PEP should not be given unless specific extenuating circumstances exist. This has been introduced as a result of feedback from the National AIDS Trust suggesting that PEP has been given for very low risk exposures as prescribers may feel anxious not to give PEP for some indications which were previously listed as *'consider'*.
6. Changes to PEP prescribing indications include the following.
  - a. Receptive vaginal sex with a partner of unknown HIV status from a high-risk group – PEP is now *'generally not recommended'*.
  - b. Insertive vaginal sex with a partner of unknown HIV status from a high-risk group – PEP is now *'generally not recommended'*.
  - c. Sharing of injecting equipment with a partner of unknown HIV status from a high-risk group – PEP is now *'generally not recommended'*.
  - d. Human bite – PEP is now *'generally not recommended'*.
7. The recommended first-line PEP regimen is tenofovir disoproxil 245 mg/emtricitabine 200 mg with raltegravir 1200 mg once daily for a minimum of 28 days.

8. In light of the fact that starter packs can negatively impact completion of PEP, the full course of PEP should be provided at the first attendance where possible to facilitate completion of the course.
9. Final HIV testing is recommended at a minimum of 45 days after the PEP course is completed. If the 28-day course is completed, this is a minimum of 73 days (10.5 weeks) after exposure. For sexual exposures, this can be performed at 12 weeks to align with syphilis testing.
10. Information on baseline and follow-up hepatitis B testing is more detailed and takes into consideration an individual's baseline hepatitis immunity through vaccination.
11. Hepatitis C virus (HCV) polymerase chain reaction (PCR) or an HCV antigen test is suggested following high-risk exposures, as antigen-based tests have a shorter window period than HCV antibody tests.
12. Indications and management of HIV PEP in the context of chronic hepatitis B virus (HBV) infection are included.
13. HIV PEP regimens for breastfeeding mothers are described.
14. Indications for use of PEP in populations using HIV PrEP are discussed.
15. A revised PEP proforma is included, the aim of which is to facilitate assessment by non-HIV specialists.
16. For ease of reference, key recommendations are available through the British HIV Association guidelines mobile phone application.

## Executive summary

This summary for clinicians assessing the need for and/or providing post-exposure prophylaxis (PEP) outlines five key areas from the British Association for Sexual Health and HIV (BASHH) 2021 UK Guideline for the use of HIV PEP.

1. When to offer PEP.
2. What PEP to prescribe.
3. When to start PEP.
4. Baseline tests.
5. Follow-up.
6. Additional considerations for all patients receiving PEP.

This summary does not cover special scenarios such as pregnancy, breastfeeding, chronic hepatitis B, and PEP in people using HIV pre-exposure prophylaxis (PrEP) – please refer to the full guideline.

### 1. When to offer PEP (Section 6)

Where the index partner is HIV positive and has been on antiretroviral therapy for at least 6 months with an

undetectable plasma HIV viral load (at the time of last measurement and within the last 6 months) and with good reported adherence, PEP is not indicated following any type of exposure.

**PEP should be routinely offered to reduce risk of HIV transmission in the following scenarios.**

1. Following receptive anal intercourse with an index partner of unknown HIV status or known to be HIV positive with an unknown or detectable HIV viral load.
2. Following receptive vaginal sex with an index partner known to be HIV positive with an unknown or detectable HIV viral load.
3. Following an occupational exposure (sharps or mucosal splash) from an index case known to be HIV positive with an unknown or detectable HIV viral load.
4. For people who inject drugs after sharing needles/equipment if their index injecting partner is known to be HIV positive with an unknown or detectable HIV viral load.

**PEP should be considered in the following circumstances.**

1. Insertive vaginal intercourse with an index partner known to be HIV positive with an unknown or detectable HIV viral load.
2. Insertive anal intercourse with an index partner of unknown HIV status.

**PEP is generally not recommended for the following scenarios and should only be considered if there is a clear specific extenuating factor which increases the risk of transmission (see Table 4).**

1. Sharps and splash injuries, sharing of injecting equipment, receptive or insertive vaginal intercourse when the index case is from a high-risk group but the HIV status is unknown.
2. Human bite if the index case is HIV positive with an unknown or detectable HIV viral load.

IN ALL OTHER SCENARIOS PEP IS NOT RECOMMENDED. For further information, see Table 4.

### 2. What PEP to prescribe (Section 7)

The first-line regimen is tenofovir disoproxil (TD) 245 mg/emtricitabine (FTC) 200 mg fixed dose combination plus raltegravir 1200 mg once daily for 28 days.

Antacids (containing aluminium, magnesium or calcium), multivitamins and iron supplements should be avoided whilst on raltegravir once daily. For further information on drug interactions, see Section 7.4 or [www.hiv-druginteractions.org/checker](http://www.hiv-druginteractions.org/checker). For alternative options where the attendee has a clinically relevant drug interaction, has renal impairment or is pregnant, or where the index case has a history of antiretroviral therapy failure, refer to Section 7 and Table 5.

### 3. When to start PEP (Section 8)

PEP should be initiated as soon as possible after exposure, preferably within 24 h. PEP should not be initiated beyond 72 h after exposure.

### 4. Baseline tests (Section 9)

#### **All exposures:**

1. creatinine [and estimated glomerular filtration rate (eGFR)];
2. alanine transaminase;
3. HIV-1 antigen (Ag)/antibody (Ab);
4. if not known to be vaccinated with documented hepatitis B surface antigen (HBsAg) > 10 IU: hepatitis B serology (HBsAg, hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb)).

**Sexual exposure:** as for 'all exposures', plus chlamydia, gonorrhoea and syphilis testing. HCV screening in men who have sex with men (MSM) and others at risk of hepatitis C.

**Occupational exposure:** as for 'all exposures' plus hepatitis C screening in all.

A pregnancy test should be performed for all women of childbearing age considering PEP.

### 5. Follow-up (Section 9)

- (1) Routine renal and liver function test monitoring after initiation of PEP is not necessary unless clinically indicated or if baseline blood tests are abnormal.
  - (2) Follow-up testing for HIV can be performed 45 days after the completion of the PEP course. If a 28-day course is completed this is a minimum of 10.5 weeks post-exposure. For sexual exposures, HIV testing can be undertaken at week 12 after the exposure to align with syphilis testing.
  - (3) Follow-up testing for hepatitis B should be guided by hepatitis B vaccination status and baseline immunity (Table 6, Figure 1).
  - (4) Chlamydia, gonorrhoea and syphilis testing following the incubation period.
  - (5) For occupational exposures, we recommend individuals are followed up by their occupational health department as soon as possible, ideally within 72 h of the event. Occupational health services are responsible for testing the index case (in conjunction with the attending clinician and according to local policies which define roles and responsibilities), supporting the individual during PEP and follow-up testing.
- #### 6. Additional considerations for all individuals receiving PEP
- (1) Provide emergency contraception where indicated.
  - (2) Hepatitis B vaccination in the absence of baseline immunity (Figure 1).
  - (3) Individuals with ongoing risk should be transitioned immediately from PEP to PrEP. Refer to an appropriate professional to discuss risk reduction (including PrEP) where appropriate.
  - (4) Reinforce the importance of good adherence and completion of the 28-day PEP course.
  - (5) Provide the BASHH leaflet on HIV PEP.

<b>Table of Contents</b>	
<i>New in the 2021 guideline</i>	2
<i>Executive summary</i>	3
<b>1 Objectives</b>	7
<b>2 Methods</b>	7
2.1 Search strategy	7
2.2 Stakeholder involvement, piloting and feedback	8
<b>3 Summary of recommendations</b>	8
<b>4 Background</b>	12
<b>4.1 Data supporting the use of PEP to prevent HIV transmission</b>	12
4.1.1 Animal studies	12
4.1.2 Human studies	12
<b>4.2 Factors influencing the efficacy of PEP</b>	13
4.2.1 Seroconversion following PEP for sexual exposures	13
4.2.2 Seroconversions following PEP for occupational exposures	13
4.2.3 Potential for transmitted drug resistance and use of PEP	14
<b>4.3 Possible risks of PEP</b>	14
4.3.1 Safety	14
4.3.2 Behavioural implications	14
<b>5 Risk of HIV transmission</b>	14
<b>5.1 Risk of HIV transmission through condomless sexual exposures</b>	14
<b>5.2 Individual-level efficacy of antiretroviral therapy to prevent the sexual transmission of HIV</b>	14
<b>5.3 Prevalence of detectable (transmissible) levels of HIV amongst specific populations in the UK</b>	15
<b>5.4 Transmission risk varies by type of exposure where the index case is known to be HIV positive and not on suppressive antiretroviral therapy</b>	15
<b>5.5 Calculating the risk of HIV transmission from a single exposure</b>	15
<b>5.6 Risk of HIV transmission following occupational exposures</b>	16
5.6.1 Definition of exposure and infectious fluid in occupational settings	16
5.6.2 Immediate actions following occupational exposure to reduce transmission risk	17
5.6.3 Needlestick and sharps injuries	17
5.6.4 Mucocutaneous exposures or splash injuries	17
5.6.5 Biting and spitting	17
<b>5.7 Risk of HIV transmission through injecting drug use</b>	19
5.7.1 Sexualized drug use	19
<b>6 When to prescribe PEP</b>	19
<b>6.1 When to prescribe PEP following sexual exposure</b>	20
6.1.1 Index partner is of unknown HIV status	20
6.1.2 Index partner known to be HIV positive	20
6.1.3 Sexual assault	22
6.1.4 Commercial sex workers	22
<b>6.2 When to prescribe following occupational exposures</b>	22
6.2.1 Sharps and mucosal splash injuries	22
6.2.2 Needlestick injuries in the community	23
<b>6.3 Human bites</b>	23
<b>6.4 People who inject drugs</b>	24

<b>Table of Contents</b>	
<b>7 What to prescribe for PEP</b>	<b>24</b>
<b>7.1 First-lines</b>	<b>24</b>
7.1.1 Nucleoside reverse transcriptase inhibitors (NRTIs)	24
7.1.2 Integrase strand transfer inhibitors (INSTIs)	25
<b>7.2 Alternative regimens</b>	<b>25</b>
7.2.1 Nonnucleoside reverse transcriptase inhibitors (NNRTIs)	25
7.2.2 Protease inhibitors (PIs)	25
7.2.3 C-C chemokine receptor type 5 (CCR5) antagonists	26
<b>7.3 Side effects</b>	<b>26</b>
<b>7.4 Drug–drug interactions</b>	<b>27</b>
<b>8 Timing and duration of PEP</b>	<b>27</b>
<b>9 How to provide HIV PEP</b>	<b>28</b>
<b>9.1 Baseline risk assessment</b>	<b>28</b>
<b>9.2 Initiating PEP</b>	<b>28</b>
9.2.1 Management of anxiety	29
<b>9.3 Baseline BBV testing of the index case</b>	<b>29</b>
<b>9.4 Baseline and follow-up testing of recipient</b>	<b>30</b>
9.4.1 Sexual health considerations	32
9.4.2 Occupational health considerations	32
<b>10 Special scenarios</b>	<b>33</b>
<b>10.1 Chronic HBV infection</b>	<b>33</b>
<b>10.2 Pregnant and breastfeeding mothers</b>	<b>34</b>
10.2.1 Breastfeeding	34
<b>10.3 Use of PEP in populations using PrEP</b>	<b>35</b>
<b>10.4 When to discontinue PEP because of missed doses</b>	<b>35</b>
<b>10.5 Seroconversion during PEP</b>	<b>36</b>
<b>10.6 Further high-risk exposures while on PEP</b>	<b>36</b>
<b>11 Recommendations for PrEP in those with ongoing high-risk behaviour</b>	<b>36</b>
<b>12 Awareness of PEP</b>	<b>37</b>
<b>13 Cost-effectiveness</b>	<b>37</b>
<b>14 Surveillance of the use of PEP</b>	<b>37</b>
<b>14.1 Sexual exposures</b>	<b>37</b>
<b>14.2 Occupational exposures</b>	<b>37</b>
<b>15 Qualifying statement</b>	<b>38</b>
<b>16 Applicability</b>	<b>38</b>
<b>17 Auditable outcome measures</b>	<b>38</b>
<b>Acknowledgements</b>	<b>38</b>
<b>Conflicts of interest</b>	<b>38</b>

## 1 | OBJECTIVES

We provide evidence-based recommendations for the most appropriate use of HIV post-exposure prophylaxis (PEP) following sexual, occupational and other nonoccupational exposures in the community to prevent HIV transmission. Risk of transmission, timing of PEP, preferred regimen, drug–drug interactions, follow-up, risk reduction and special scenarios are discussed. Consideration is given to the role of PEP within the broader context of HIV prevention strategies and sexual health. We also provide guidance on PEP use in people who inject drugs (PWID), particularly sexualized drug use, which has become an increasingly reported phenomenon since the prior guideline.

This is the first time that PEP following occupational exposures has been discussed within the British Association for Sexual Health and HIV (BASHH) guidelines; the intention is to harmonize PEP use and delivery across the disciplines to ensure high-quality, streamlined PEP clinical care pathways underpinned by evidence-based guidelines. The guideline is intended to supersede the 2013 Department of Health and Expert Advisory Group on AIDS (EAGA) guidance on PEP in occupational settings [1].

This guideline is aimed primarily at clinicians and policy-makers in occupational health, sexual health, sexual assault referral centres (SARCs), and primary and emergency care providers within the UK. The guideline is intended to support the development of appropriate local care pathways for PEP. It is likely that it will also be used for information provision by voluntary sector agencies to provide information for individuals. The recommendations are aimed primarily at individuals aged 16 years or older, or adolescents deemed Gillick competent by the prescribing clinician, and may not be appropriate for use in all situations. Decisions to follow these recommendations must be based on the professional judgment of the clinician and consideration of individual patient circumstances.

## 2 | METHODS

The multidisciplinary guideline working group developed the guidelines based on processes outlined in the BASHH Framework for Guideline Development [2]. The guideline is based on a comprehensive literature review on PEP and HIV transmission. All writing group members underwent Grading of Recommendations Assessment, Development and Evaluation (GRADE) training. The

strength of the recommendation is graded as 1 (strong) or 2 (weaker / conditional) and the quality of the evidence is graded from A (high-quality) to D (low-quality) as is further detailed in Appendix C. Good practice points (GPP) are recommendations based on the clinical judgement of the working group.

The recommendations are the result of a series of face-to-face and virtual meetings of the writing committee and incorporate input from the public consultation process (comments available on request).

The population intervention comparator outcome (PICO) framework was utilized with the question formulated as follows.

- **POPULATIONS:** HIV-negative individuals at potential risk of acquiring HIV following sexual, occupational (percutaneous injury/mucosal or cutaneous exposure to infectious body fluid) or nonoccupational needlestick exposure (injecting drug use) or bite.
- **INTERVENTION:** post-exposure prophylaxis, PEP, PEP following sexual exposure (PEPSE) or antiretroviral therapy (ART).
- **COMPARISON:** no intervention, ART treatment as prevention (TasP), condoms or pre-exposure prophylaxis (PrEP).
- **OUTCOME:** HIV infection, seroconversion, toxicity, adherence, sexual behaviour or cost-effectiveness.

### 2.1 | Search strategy

Current BASHH [3], USA Centers for Disease Control and Prevention [4], World Health Organization [5], Health Service Executive Ireland and Australian Society of HIV Medicine guidelines were reviewed [6]. New literature on the following topics, arising since the time of the last guideline development, was sought through comprehensive literature review using Medline, Embase and Cochrane Library by a trained medical librarian (TR):

1. HIV PEP following sexual exposures: all articles from January 2014 to February 2019 (265 abstracts reviewed).
2. Occupational exposures: the search dated back to 2008.
3. Injecting drug use.
4. Hepatitis B.
5. Pregnancy and breastfeeding.
6. PrEP and PEP.

Search terms for each search are included in supplementary materials. Conference abstracts from Conference

on Retroviruses and Opportunistic Infection (CROI), International AIDS Conference, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and HIV Drug Therapy from 2014 to 2019 were reviewed. For study selection, a two-stage sifting process was employed: (1) at title and abstract level, and (2) at full text level. All studies reporting on PEP were considered with the following exclusion criteria applied: (1) any study not written in English and (2) narrative reviews not adding new data or new analysis of data to existing knowledge. Sifting was performed in duplicate independently by two reviewers.

## 2.2 | Stakeholder involvement, piloting and feedback

The guideline working group included representatives from the BASHH, British HIV Association (BHIVA), Expert Advisory Group on AIDS (EAGA), Society of Sexual Health Advisers (SSHA), HIV Pharmacy Association (HIVPA), Terrence Higgins Trust (THT), National AIDS Trust (NAT) and Public Health England (PHE). Patients' perspectives will be considered by involvement of THT and NAT, reviewing the literature for information from patient surveys and the public consultation process.

## 3 | SUMMARY OF RECOMMENDATIONS

### Section 6: When to prescribe PEP

6.1 When to prescribe PEP following sexual exposure		GRADE*
1	We recommend the use of PEP following sexual exposure where there is a significant risk of HIV transmission (Table 4).	1C
2	The risks and benefits of providing PEP for adolescents should be weighed carefully in the context of UK laws and judgements about autonomy in health care decision-making (e.g. Gillick competency), and balanced against protecting young people from harm.	GPP
6.1.1 Index partner is of unknown HIV status		
3	Proactive attempts should be made to establish the HIV status of the index partner; this should not, however, delay initiation of PEP where indicated (Table 4).	1C
6.1.2 Index partner known to be HIV positive		
4	Attempts should be made at the earliest opportunity to determine the plasma HIV viral load, resistance profile and treatment history of the index partner.	GPP
5	PEP is not recommended if the index partner has been on ART for at least 6 months with an undetectable plasma HIV viral load (at the time of last measurement and within the last 6 months) and with good reported adherence	1A
6	Individuals should be encouraged to undergo a formal PEP assessment and verification of index partner's HIV details even when they believe the partner has an undetectable HIV viral load.	GPP
7	If there are any doubts about the ART history, the index partner's adherence to ART or the viral load, then PEP should be given following condomless receptive anal intercourse.	GPP
6.2 When to prescribe following occupational exposures and other nonoccupational exposures in the community.		
6.2.1.1 Sharps and mucosal splash injuries with an index case known to be HIV positive		
8	PEP is recommended following a high-risk injury (sharps or mucosal splash) if the index case is known to be HIV positive and has not been on ART for > 6 months with a suppressed viral load within the last 6 months.	1C
9	PEP is generally not indicated following a sharps injury if the index case has been on ART for at least 6 months with an undetectable plasma HIV viral load (at the time of last measurement and within the last 6 months) and with good reported adherence; however, because of lack of direct evidence, a case-by-case decision can be made depending on the nature of the injury.	2C
10	PEP is not recommended following a splash injury if the index case is known to have a sustained undetectable viral load.	1C
11	PEP is not recommended where there is no or negligible risk of HIV transmission, e.g. through intact skin that comes into contact with HIV-infected blood or other bodily fluids.	1C
6.2.1.2 Sharps and mucosal splash injuries with an index case of unknown HIV status		
12	PEP is not recommended following a sharps or mucosal splash injury if the index case is untested but from a low-risk group (Table 4).	1C
13	PEP is generally not recommended following a sharp or mucosal splash injury if the index case is untested and from a high-risk group (e.g. MSM or PWID), unless there were other factors that increased the likelihood of transmission (e.g. a deep injury or blood bolus injected or a sharps injury from a PWID in the context of a local outbreak) (Table 4).	1C
14	All efforts should be made to seek prompt voluntary HIV testing of the index case.	1C



15	Testing the index case should not delay PEP initiation where indicated.	GPP
16	If the index case is unable to give informed consent for HIV testing (e.g. unconscious or altered mental status) then HIV testing can be performed if it is in the best medical interest of the index case.	GPP
<b>6.2.2 Needlestick injuries in the community</b>		
17	PEP is not recommended following a community needlestick exposure.	2D
<b>6.3 When to prescribe PEP following human bites</b>		
18	In general, PEP is not recommended following a bite as, although the precise risk of transmission is unknown, it is likely to be negligible.	2D
19	However, PEP could be considered for patients who fulfil ALL of the following three criteria: (a) the biter's saliva was visibly contaminated with blood; (b) the biter is known or suspected to have a plasma HIV viral load > 3.0 log copies/mL; and (c) the bite has resulted in severe and/or deep tissue injuries.	2D
<b>6.4 When to prescribe PEP to people who inject drugs (PWID)</b>		
20	Individuals who report the use of any injectable drugs should be asked specifically if they are currently injecting and, if so, whether equipment is ever shared.	GPP
21	The HIV status and, if positive, viral load and ART history of their injecting partners should be ascertained.	GPP
22	PEP is recommended for PWID after sharing needles/equipment if their index injecting partner is HIV positive and has not been on ART for > 6 months with a suppressed viral load.	1C
23	PEP is generally not recommended in PWID after sharing needles/equipment with an injecting partner of unknown HIV status from a high-prevalence country/risk group, but PEP can be considered on a case-by-case basis for PWID in the context of a localized outbreak.	GPP
24	Existing harm-reduction strategies such as needle exchange and opiate substitution programmes should be encouraged for PWID.	1D
25	MSM should be specifically asked about chemsex and injecting drug use.	GPP
<b>Section 7: What to prescribe for PEP</b>		
<b>7.1 First-lines</b>		
26	We recommend the use of TD 245 mg/FTC 200 mg and raltegravir 1200 mg once daily as the regimen of choice for PEP (Table 5).	1B
27	If there is evidence that the index case has a current or past history of ART failure, expert advice should be sought as to whether the PEP regimen should be modified in relation to ART history and/or resistance testing.	1D
28	For women who are pregnant or at risk of pregnancy, raltegravir 400 mg twice daily is preferred (with TD 245 mg/FTC 200 mg). Where accessing raltegravir 400 mg might cause delay, we recommend using raltegravir 600 mg twice daily and switching at the earliest opportunity.	1D
<b>7.3 Side effects</b>		
29	Where an individual reports significant current or previous intolerance to one or more PEP agents, an alternative agent(s) should be considered.	2D
<b>7.4 Drug–drug interactions</b>		
30	An accurate verified medication history should be obtained, including the use of over-the-counter medication, vitamins/minerals, herbal remedies and recreational drugs before PEP is prescribed to ensure no significant drug–drug interactions are present.	1D
<b>Section 8: Timing and duration of PEP</b>		
31	PEP should be initiated as soon as possible after exposure, preferably within 24 h, but can be considered up to 72 h.	1D
32	We do not recommend initiating PEP beyond 72 h after exposure.	1D
33	The duration of PEP should be 28 days.	1D
<b>Section 9: How to provide HIV PEP</b>		
34	For PEP to be maximally effective, a 24-h service is recommended.	1C
35	It is recommended that local policies include 24-h access to advice from an experienced HIV clinician, particularly for complex cases.	1D
<b>9.2 Initiating PEP</b>		
36	Routine safety blood test monitoring after initiation of integrase inhibitor-based PEP is not necessary unless clinically indicated or if baseline blood tests are abnormal.	2C

- 37 Take a contraceptive history and perform pregnancy testing in all women of childbearing age considering PEP and offer emergency contraception where indicated. 1D
- 38 Pregnancy and breastfeeding should not alter the decision to start PEP. 2D
- 39 Women must be counselled that antiretroviral agents used for PEP are unlicensed in pregnancy and their risks/benefits must be carefully discussed (see Section 10.2). 1D
- 40 An ultra-rapid course of HBV vaccination should be offered if clinically indicated in the absence of baseline immunity (see Figure 1, Section 9.4.2) 1B
- 41 Use of starter packs can negatively impact the completion of PEP, and therefore a full course of PEP should be provided at the first attendance unless there are operational reasons why this is not possible. 1C

### 9.3 Baseline blood-borne virus (BBV) testing of the index case

- 42 Following occupational exposures, informed consent for testing for BBVs (fourth-generation HIV test [HIV-1 antigen (Ag)/antibody (Ab)], HBV surface antigen (HBsAg) or HCV antibody (HCV Ab)) should be sought from the index case by another member of staff who is not the recipient of the occupational exposure. GPP
- 43 If the index case is a child, then age-appropriate HIV, HBV and HCV testing should be used, depending on the age and developmental stage of the child, consent from the parent or legal guardian of the child, and consent or assent from the child. Discuss with a clinician with relevant expertise (e.g. paediatrician or paediatric infectious diseases/microbiologist/virologist) if uncertain. GPP
- 44 Where the index case is high risk for hepatitis C (e.g. PWID), then an HCV polymerase chain reaction (PCR) or HCV antigen (HCV Ag) test can be done instead of HCV Ab. GPP
- 45 Where it is not possible to seek consent from the index case (e.g. patient comatose or lacks mental capacity), then testing can be undertaken if it is in the best medical interests of the index case. GPP

### 9.4 Baseline and follow-up blood testing of recipient

- 46 Baseline and follow-up tests are summarized in Table 6. 1B  
**All exposures:** blood testing before PEP initiation should include creatinine (and eGFR), alanine transaminase, HIV-1 Ag/Ab and HBV serology (if not known to be immune with HBsAb > 10 IU). PEP initiation should not be delayed by waiting for blood results.  
**Sexual exposure:** tests listed in 'All exposures' plus syphilis serology and HCV Ab in MSM and others at risk of hepatitis C.  
**Occupational exposure:** tests listed in 'All exposures' plus HCV Ab in all.
- 47 Baseline pregnancy test in women of childbearing age considering PEP. 1D
- 48 Routine renal and liver function test monitoring after initiation of PEP is not necessary unless clinically indicated or if baseline blood tests are abnormal. 2C
- 49 Follow-up testing for HIV should be undertaken at a minimum of 45 days after completion of the PEP course. If the 28-day PEP course is completed, this is 73 days (10.5 weeks) post exposure. 1B
- 50 Follow-up testing for hepatitis B should be guided by hepatitis B vaccination status and baseline immunity as shown in Table 6, Section 9.4.1 and Figure 1, Section 9.4.2. 1b
- 51 For occupational exposures, after initiating PEP, we recommend individuals are followed up by their occupational health department as soon as possible, ideally within 72 h of the event. 1D

### 9.4.3 Sexual health considerations

- 52 Perform chlamydia, gonorrhoea and syphilis testing (based on clinical situation) at baseline and repeat testing following the incubation period. 2C
- 53 Emergency contraception should be offered where indicated. 1B
- 54 Offer MSM hepatitis A and human papilloma virus vaccines (in addition to HBV vaccine) if clinically indicated as per the 2016 BASHH men who have sex with men guidance. 1B
- 55 Individuals presenting for PEP may be at higher risk of future acquisition of HIV and should be encouraged to attend for regular sexual health checks and considered for referral to risk-reduction services including HIV PrEP. 2C
- 56 Provision of PEP should be fully integrated into counselling around safer sex strategies, including the opportunity to meet with an appropriate health care professional competent in sexual health advising. 1C

## Section 10: Special scenarios

### 10.1 Chronic HBV infection

- 57 Baseline HBV testing should be undertaken in those of unknown HBV status, and vaccination [and HBV immunoglobulin (HBIG), depending on risk of exposure] initiated in those who are not known to be immune whilst awaiting results. GPP

58	Consider the use of a standard PEP regimen for individuals known to have chronic HBV infection and on either nucleoside reverse transcriptase inhibitor-based [except if on combined therapy with tenofovir (TDF)/lamivudine or TDF/FTC] or pegylated interferon (IFN)-alpha-based HBV treatment, where high-risk HIV exposure has occurred.	1B
59	Individuals found to have HBV infection at baseline should receive PEP as needed without delay.	1B
60	Individuals found to be HBV infected at baseline should be assessed by a specialist in HBV infection with regard to continuing HBV therapy post PEP. If the hepatitis assessment does not fall within the 28-day PEP course then TDF/FTC should be continued pending the assessment.	1B
<b>10.2 Pregnant and breastfeeding mothers</b>		
61	Take a contraceptive history and request a baseline pregnancy test in women of childbearing age considering PEP.	1D
62	Pregnancy and breastfeeding should not alter the decision to start PEP.	2D
63	For women who are pregnant, raltegravir 400 mg twice daily is preferred (with TD 245 mg/FTC 200 mg). Where accessing raltegravir 400 mg might cause delay, we recommend using raltegravir 600 mg twice daily and switching at the earliest opportunity.	1C
64	For women at risk of pregnancy or known to be within the first 6 weeks of pregnancy who cannot use first-line therapy for PEP for any reason, we recommend avoiding the use of dolutegravir as an alternative third agent (Table 5, Section 7).	1C
65	For women beyond 6 weeks of pregnancy, dolutegravir can be used as an alternative third agent.	1C
66	Women should be counselled that antiretrovirals used for PEP are unlicensed in pregnancy and that their risks/benefits must be carefully discussed (see Section 10.2).	1D
67	Women who are breastfeeding must be counselled regarding the transfer of antiretrovirals to the infant via the breastmilk.	1D
<b>10.3 Use of PEP in populations using PrEP</b>		
68	The need for PEP (i.e. a significant potential risk within the last 72 h) should be considered in all individuals requesting PrEP, prior to transitioning to PrEP.	1B
69	Decisions about the need for PEP in the setting of people on PrEP but with less than optimal PrEP adherence depend on length of time since the last dose of PrEP and the site of exposure.	1C
70	Anal sex: if the only exposure has been through anal sex and where fewer than four tablets have been taken within the last 7 days or where the last dose was > 7 days ago, PEP is recommended.	1A
71	Vaginal sex: where the potential HIV exposure is through vaginal sex and PrEP adherence has been suboptimal, PEP should be considered if > 48 h has elapsed since last dosing or if fewer than six tablets have been taken within the previous 7 days.	1B
72	Frontal or neovaginal sex: where the potential exposure to HIV is through frontal sex in trans men or through neovaginal sex in trans women, then PEP should be considered if > 48 h has elapsed since last dosing or if fewer than six tablets have been taken within the previous 7 days.	1C
<b>10.5 Seroconversion during PEP</b>		
73	Individuals experiencing a skin rash or flu-like illness while or after taking PEP should be advised to attend for urgent review to exclude an HIV seroconversion.	2D
74	If the HIV test is positive after PEP has already been initiated, PEP should be continued pending review by an HIV specialist.	GPP
<b>10.6 Further high-risk exposures while on PEP</b>		
75	In the event of a further high-risk sexual exposure during the last 2 days of the PEP course, PEP should be continued until 48 h after the last high-risk exposure for anal sex or until 7 days after the last high-risk exposure for vaginal/frontal sex.	2B
<b>Section 11: Recommendations for PrEP in those with ongoing high-risk behaviour</b>		
76	Repeat attenders should meet with a sexual health adviser and/or psychologist and provision of PEP should be fully integrated into counselling around safer sex strategies.	1C
77	PEP should not be considered or encouraged as a first-line method of HIV prevention.	1C
78	Individuals presenting for PEP who are likely to have ongoing high-risk behaviour should be transitioned immediately to PrEP. HIV testing with a combined Ag/Ab laboratory-based assay should be performed at the time of transition.	GPP

\*The strength of the recommendation is graded as 1 (strong) or 2 (weaker / conditional) and the quality of the evidence is graded from A (high-quality) to D (low-quality) as is further detailed in Appendix C. Good practice points (GPP) are recommendations based on the clinical judgement of the working group.

## 4 | BACKGROUND

Pathogenesis studies indicate that there may be a window of opportunity to prevent acquisition of HIV infection following exposure by inhibiting viral replication or preventing dissemination of infection, if ART is started as soon as possible (Figure 1). Once HIV crosses a mucosal barrier, it may take up to 48 h before it begins to replicate and up to 5 days before HIV can be detected in blood [7-9]. Initiation of ART has been shown to reduce dissemination and replication of virus in tissues if initiated early (< 72 h) after inoculation in a macaque animal model, although HIV infection is not universally prevented even if PEP is initiated within 4 h [10].

### 4.1 | Data supporting the use of PEP to prevent HIV transmission

#### 4.1.1 | Animal studies

Animal studies provide evidence for PEP efficacy and demonstrate the importance of time to initiation and duration of therapy. Differences in study design, size of inoculum and modes of administration may account for differing results, but the key points are that PEP is most effective when administered within 24 h of exposure, with


possible efficacy up to 72 h post exposure, and with a duration of 28 days [11-14].

#### 4.1.2 | Human studies

Prospective randomized controlled trials (RCTs) to determine the efficacy of PEPSE have not been performed and are not feasible as a consequence of the ethics of withholding a potentially efficacious treatment. However, important data informing understanding of PEP efficacy in humans are available from an observational study of PEP following sexual exposures, data on occupational PEP use and studies on vertical transmission.

##### 4.1.1.1 | Occupational exposure to HIV

A retrospective case-controlled study among health care workers (HCWs) occupationally exposed to HIV between 1983 and 1994 demonstrated that a 28-day course of zidovudine was highly protective, resulting in an 80% reduction in HIV seroconversions compared to those who did not receive PEP [odds ratio (OR) 0.19; 95% confidence interval (CI) 0.06–0.52] [15]. Since 1997, when the surveillance of serious occupational exposures began, there has been only one documented case in the UK of HIV seroconversion in an



**FIGURE 1** Flow chart illustrating hepatitis B virus (HBV) baseline testing and follow-up. \*Higher risk source includes people who inject drugs, men who have sex with men, and people from high-prevalence countries. Health care workers, emergency workers and prison service staff should have been routinely vaccinated as part of occupational health requirements. HBIG, HBV immunoglobulin; HBsAb, HBV surface antibody; HBsAg, HBV surface antigen

HCW after occupational exposure, in 1999, despite the use of combination PEP; however, the index case was highly treatment experienced [16]. Data from UK HPA from 2004 to 2013 showed that there were 4830 health care-associated occupational exposures to body fluid reported in the UK, 71% of which were percutaneous injuries. During this time, 598 HCW were started on HIV PEP, of whom 97% (580/598) were started within 72 h following occupational exposure to HIV. There were no new cases of HIV infection during follow-up [17, 18]. The rare cases where PEP has failed to prevent HIV infection following occupational exposure are largely historical [19–21]. Factors that have contributed to PEP failure are discussed in **Section 4.2**.

#### 4.1.1.2 | *Sexual exposure to HIV*

Clinical effectiveness evidence for PEPSE is weak as a consequence of both the paucity and poor quality of data available. A systematic review published in 2009 [22] included only a single observational study of PEPSE use in high-risk MSM in Brazil. Participants were given a 4-day ‘starter pack’ of zidovudine and lamivudine and instructed to begin PEP immediately after exposure. For eligible exposures, an additional 24-day supply was subsequently provided. PEP was initiated 109 times by 68 participants over a 2-year period. HIV incidence in the cohort as a whole (2.9 per 100 person-years) was very similar to that expected in this population (3.1 per 100 person-years;  $P > 0.97$ ). However, only one seroconversion (1.4%) occurred in the PEP group ( $n = 68$ ) compared to 10 (7.5%) in the group not receiving PEP ( $n = 132$ ). The single PEP failure in the PEP group was thought to be attributable to transmitted resistance to lamivudine (M184V mutation detected) [23].

In the EXPLORE study (2010), a behavioural intervention trial in 4295 MSM which assessed the use of nonoccupational PEP over 4 years in six cities across the USA, no association was found between risk of HIV seroconversion and PEP use. Three seroconversions occurred at 384 visits (1.56 per 100 person-years) with PEP use compared to 210 seroconversions in the 25 550 visits (1.64 per 100 person-years) with no PEP use (hazard ratio 0.91; 95% CI 0.29, 2.86) [24]. However, a number of factors influence the efficacy of PEP (**Section 4.2**).

#### 4.1.1.3 | *Injecting drug use and sharps injuries*

There are very limited data on PEP efficacy in PWID. Much of the data on PEP use in PWID is limited to retrospective analyses of PEP use in the nonoccupational exposure setting, of which PWID contribute to a minority of cases [25].

## 4.2 | Factors influencing the efficacy of PEP

### 4.2.1 | Seroconversion following PEP for sexual exposures

When it is initiated promptly and taken appropriately and when repeat exposures are avoided, PEP is likely to be highly effective. From 2015 to 2018, a number of cohort studies have reported on the clinical outcomes in people receiving PEP for sexual exposures [26–31]. In the cohorts described, seroconversions most commonly resulted from ongoing risk behaviour after completing PEPSE.

Reported reasons for HIV seroconversion include:

- delayed initiation of PEP [11, 12, 15, 26, 32, 33]
- poor/non-adherence to PEP regimen [32]
- further high-risk sexual exposures after cessation of PEP [26, 28, 29]
- early primary HIV infection already established at the time of PEP initiation [34]

In a recent case series of 19 HIV diagnoses after PEPSE initiation, it was found that only one was a chemoprophylactic failure related to suboptimal dosing of lopinavir/ritonavir (LPV/r) in the first week of treatment; the other 18 had primary HIV at baseline [34]. PEP completion rates to 28 days have been historically poor in the UK (range 42–82%), although the use of the less tolerable drugs in these studies may have had an impact [35–44]. A 2017 cohort study using a single-tablet regimen of elvitegravir/cobicistat/tenofovir disoproxil (TD)/emtricitabine (FTC) for PEP found that 71% of study participants completed the course; this was higher than historical completion rates with raltegravir-based PEP (57%) and protease inhibitor (PI)-based PEP (39%), both of which required twice-daily dosing; despite this, no seroconversions occurred with all regimens [30]. Adherence counselling and support therefore remain a central component of PEP provision.

### 4.2.2 | Seroconversions following PEP for occupational exposures

As mentioned above, there have been no cases of occupational HIV transmission in the UK since 1999. PEP failure in this case report was thought to be attributable to transmission of resistant HIV. The source patient was treatment experienced and had a high viral load with evidence of genotypic resistance. PEP

(zidovudine, lamivudine and indinavir) was initiated within 2 h of the penetrating needlestick injury but seroconversion was confirmed at 3 months. [16, 18]. In Australia, there has been a more recent occupational transmission, despite prompt PEP initiation, as a result of an inoculum of HIV-infected blood being accidentally injected into the finger pulp of a nurse during a sharps injury [21].

#### 4.2.3 | Potential for transmitted drug resistance and use of PEP

In 2016, the prevalence of transmitted drug resistance (TDR) in diagnosed PLWH in the UK increased slightly compared to previous years; 9.6% of persons tested had any detectable drug resistance mutation [45, 46]. The prevalence of transmitted resistance mutations for PIs remained low and stable at 2.2%. There was a small rise from the previous year (2015) in the prevalence of NRTI resistance-conferring mutations from 3.4% to 4.2%, and for nonnucleoside reverse transcriptase inhibitors (NNRTIs) from 3.3% to 4.1%. TDR to the integrase strand transfer inhibitor (INSTI) class is considered rare but data are limited by lack of routine baseline testing. Only one major INSTI mutation was detected in 96 baseline INSTI sequences in a study in the west of Scotland [47]. Unpublished data from the UK Drug Resistance Database demonstrate only one major mutation in approximately 1000 baseline sequences (personal communication from Anna Tostevin, Oliver Stirrup & David Dunn, February 2020).

### 4.3 | Possible risks of PEP

#### 4.3.1 | Safety

Currently recommended PEP regimens are very safe and well tolerated. However, the potential benefit of PEP must be balanced with the possibility of side effects or toxicity, taking into account any comorbidities.

#### 4.3.2 | Behavioural implications

Historically, there were concerns that PEP availability would undermine other prevention strategies such as condom use. However, the EXPLORE study, a behavioural intervention trial in the USA in 4295 MSM which assessed perceptions and use of PEP over 4 years, demonstrated that previous PEP use was not associated with higher odds of high-risk sex [24].

## 5 | RISK OF HIV TRANSMISSION

### 5.1 | Risk of HIV transmission through condomless sexual exposures

The risk of HIV transmission following a sexual exposure depends on:

1. the type of sexual exposure;
2. the HIV viral load of the index partner;
3. the susceptibility of the recipient if the sexual partner is not virologically suppressed, e.g. genital ulcer disease [48].

Where individuals have multiple exposures within 72 h, it is important to consider the potential for increased risk.

Table 1 (Section 5.3.1) shows the estimated prevalence of people with detectable HIV viraemia (including both diagnosed and undiagnosed infection) in adults aged 15–74 years in the UK in 2018. Latest HIV prevalences in other countries can be found on the website <https://aidsinfo.unaids.org>

### 5.2 | Individual-level efficacy of ART to prevent the sexual transmission of HIV

There is now compelling data from a number of studies in a variety of geographical settings indicating that virological suppression prevents transmission of HIV to sexual partners. HPTN-052 was an RCT amongst serodifferent heterosexual couples randomized to early or delayed (CD4 guided) ART with 8509 person-years of follow-up in the HIV-negative partners. Early ART resulted in a 93% lower risk of within-couple transmission (hazard ratio 0.07; 95% CI 0.02–0.22). There were eight phylogenetically linked transmissions in the early ART arm, but four occurred in the initial period of ART prior to viral suppression and four much later (> 3 years), when the index cases had treatment failure and detectable viral load. Crucially, there were no documented transmissions while the index case was virologically suppressed (defined as HIV-1 viral load < 200 copies/mL) [49]. However, self-reported condom use was also high in this study, with participants reporting not using condoms for a total of only 63.4 couple-years of follow-up (CYFU).

The Europe-wide PARTNER study was a prospective, observational study in two phases. PARTNER1 recruited both gay and heterosexual serodifferent couples from 2010 to 2014, and PARTNER2 recruited and followed MSM couples from 2014 to 2018. In PARTNER1, no phylogenetically linked transmissions were found in 888 serodifferent couples (548 heterosexual and 340 gay couples)

**TABLE 1** Number and prevalence of people with detectable (transmissible) levels of HIV per 1000 population aged 15–74 years, England 2018

	Estimated number of people with detectable HIV virus <sup>a</sup>	Estimated population size	Rate per 1000
<b>Gay and bisexual men</b>			
England	12,000	518,050	23.0
London	5000	155880	32.1
Elsewhere	7000	361090	20.9
<b>Heterosexual men</b>			
Black African	1900	331950	5.8
Non-black African	3840	19,563,630	0.2
<b>Heterosexual women</b>			
Black African	3240	373330	8.7
Non-black African	2530	20,308,360	0.1
<b>PWID</b>			
All	700	104,470	6.7
Men	400	77,340	5.3
Women	300	26,710	11.5

The table is based on Public Health England 2018 data.

The number of diagnosed persons is based on the HIV & AIDS Reporting System (HARS).

Estimates of undiagnosed numbers are from multi-parameter evidence synthesis (MPES) using the upper bound of the estimates to be conservative.

PWID, people who inject drugs.

<sup>a</sup>Viral load undetectable is defined as <200 copies/mL and anything above this figure is considered detectable and ‘transmissible’. Assumptions have been made that all persons living with undiagnosed HIV infection have detectable (transmissible) virus. Added to this is the number of persons living with diagnosed HIV infection who did not have evidence of undetectability in 2018 (either because of treatment failure, not having started ART, not being retained in care or missing viral load measurement).

during 1238 eligible CYFU when the positive partner was on virally suppressive ART with a plasma HIV-1 RNA < 200 copies/mL [50].

In PARTNER1, the upper 95% confidence limit for the transmission rate for MSM was 0.84/100 CYFU, almost double that for heterosexual couples at 0.46/100 CYFU. PARTNER2 therefore continued recruitment and follow-up only in gay men from 2014 to 2018 to improve the precision of transmission risk estimates in gay sero-different partnerships. After 782 MSM couples provided 1593 eligible CYFU including 76 088 reported episodes of condomless sex, there were zero phylogenetically linked within-couple transmissions, reducing the upper 95% confidence limit to 0.23/100 CYFU.

The Opposites Attract observational study also reported zero cases of HIV transmission in MSM couples during 232 CYFU when condomless anal intercourse

was reported, HIV positive partners were virally suppressed and HIV-negative partners did not use PrEP [51].

In light of this definitive evidence, it is clear that that risk of HIV transmission from an HIV positive individual on suppressive ART through condomless sex is effectively zero regardless of sexual orientation. This concept has gained attention as ‘undetectable = untransmissible’ (‘U=U’), after the launch of a global campaign. The U=U global consensus statement has to date been endorsed by over 900 organizations in 100 countries.

### 5.3 | Prevalence of detectable (transmissible) levels of HIV amongst specific populations in the UK

In England, the number of people living with undiagnosed HIV infection is at an all-time low (see Table 1, section 5.3.1). The vast majority of PLWH are diagnosed and on treatment and are virally suppressed (> 85% of total PLWH in the UK are on ART and have suppressed infection). The estimated prevalence of detectable HIV viraemia among PLWH is therefore low. In 2018, in England, an estimated 12 000 MSM aged 15–74 years were living with HIV with detectable virus. This represents a prevalence of detectable HIV viraemia of 23 per 1000 MSM (aged 15–74 years), and the highest prevalence was among MSM living in London (32/1000 for those aged 15–74 years; see Table 1). The estimated prevalence of detectable HIV viraemia was considerably lower in other populations (Table 1).

### 5.4 | Transmission risk varies by type of exposure where the index case is known to be HIV positive and not on suppressive antiretroviral therapy

The risk of HIV transmission per exposure from a known HIV positive individual not on suppressive ART is summarized in Table 2.

### 5.5 | Calculating the risk of HIV transmission from a single exposure

The risk of an individual acquiring HIV following an exposure can be calculated by multiplying the risk that the index case is HIV positive with a detectable viral load (Table 1) and the risk per exposure (Table 2):

Risk of HIV transmission = risk that source is HIV positive with a detectable HIV viral load × risk per exposure

**TABLE 2** Risk of HIV transmission per exposure from a known HIV positive individual not on suppressive antiretroviral therapy (ART)

Type of exposure	Estimated risk of HIV transmission per exposure from an HIV positive individual who is NOT on suppressive ART <sup>a</sup>	References
Receptive anal intercourse	1 in 90	[52-58]
Receptive anal intercourse with ejaculation	1 in 65	[52-59]
Receptive anal intercourse with no ejaculation	1 in 170	[59]
Insertive anal intercourse	1 in 666	[52, 54, 55, 60]
Insertive anal intercourse, not circumcised	1 in 161	[59]
Insertive anal intercourse and circumcised	1 in 909	[59]
Receptive vaginal intercourse	1 in 1000	[52, 57, 61-67]
Insertive vaginal intercourse	1 in 1219	[56, 57, 61-67]
Semen splash to eye	<1 in 10,000	[68]
Receptive oral sex (giving fellatio)	< 1 in 10,000	[55, 62, 67, 68]
Insertive oral sex (receiving fellatio)	< 1 in 10,000	[54, 67]
Mucocutaneous	1 in 1000	[69]
Blood transfusion (one unit)	1 in 1	[70]
Needlestick injury	1 in 333	[15, 68, 71]
Sharing injecting equipment (includes chemsex)	1 in 149	[69]
Human bite	<1 in 10,000	[72, 73, 74]

<sup>a</sup>These figures are estimates that have been deduced from cohort and modelling studies.

For example, if a man presents for PEP following condomless receptive anal sex with ejaculation with a male partner of unknown HIV status in London:

$$\text{Risk of HIV transmission} = 32/1000 \times 1/65 = 32/65000 = 1/2031 \text{ (or 0.05\%)}$$

If the index case is not on suppressive ART, certain factors may further increase the risk of HIV transmission and must be considered and discussed in a PEP consultation (see Box 1).

## 5.6 | Risk of HIV transmission following occupational exposures

### 5.6.1 | Definition of exposure and infectious fluid in occupational settings

In an occupational setting, 'exposure' means contact with potentially infectious bodily fluids or tissue which poses risk of transmission of HIV through either:

#### **Box 1 Factors increasing the risk of HIV transmission if the index case is HIV positive and not on ART**

1. A high plasma HIV viral load in the index case – with each  $\log_{10}$  increase in plasma HIV RNA the per-act risk of transmission is increased 2.9-fold (95% CI 2.2–3.8) [75]. This may be particularly relevant during primary HIV infection [62].
2. Breaches in the mucosal barrier such as mouth or genital ulcer disease and anal or vaginal trauma following sexual assault or first intercourse [76, 77].
3. Menstruation or other bleeding – theoretical risk only.
4. Pregnancy or postpartum – per-act probability of HIV acquisition is higher in late pregnancy [adjusted relative risk (aRR) 2.82;  $P = 0.01$ ] and the postpartum period (aRR 3.97;  $P = 0.01$ ) as compared to that during the nonpregnant period.[78]
5. Sexually transmitted infections in HIV positive individuals not on ART [79, 80] or HIV-negative individuals with genital ulcer disease [81].



- A a percutaneous injury (e.g. a needlestick or cut with a sharp instrument contaminated with the index case's blood or other bodily fluids),
- B a mucous membrane (e.g. splash injury to the eye) or nonintact skin (e.g. exposed skin that is abraded or afflicted with dermatitis) exposure, or
- C a bite if the skin is broken as a result of trauma.

Body fluids implicated in the transmission of HIV are: blood, semen, vaginal secretions and other body fluids contaminated with visible blood. Other body fluids that could be potentially infectious are cerebrospinal, synovial, pleural, peritoneal, pericardial and amniotic fluid. Fluids that are not considered infectious (unless they contain blood) include faeces, nasal secretions, saliva, gastric secretions, sputum, sweat, tears, urine and vomit [82].

### 5.6.2 | Immediate actions following occupational exposure to reduce transmission risk

Following an exposure to blood or other body fluids, the exposed site should be immediately cleansed as follows.

1. For skin exposures, the site should be washed with soap and water. Small wounds and punctures may also be cleansed with an antiseptic, for example an alcohol-based hand hygiene solution. Alcohol is virucidal to HIV, HBV and HCV. Other antiseptics, such as iodophors, chloroxylenol and chlorhexidine, also inactivate HIV [83].
2. In cases of mucosal exposure, the exposed mucous membranes should be flushed with a copious amount of water. Eyes should be irrigated with saline or water.

Squeezing the wound to express blood is not recommended.

### 5.6.3 | Needlestick and sharps injuries

The risk of HIV transmission from a percutaneous exposure ('sharps injury') from an HIV positive index case not on suppressive ART is estimated to be 0.3% (1 in 333) [15, 84]. A pooled analysis of prospective studies in HCWs published in 1997 identified factors associated with increased odds of HIV seroconversion [15, 84], as follows.

1. Deep injury (OR 15; 95% CI 6.0–41).
2. A device visibly contaminated with the patient's blood (OR 6.2; 95% CI 2.2–21).

3. Needle placement in a vein or artery (OR 4.3; 95% CI 1.7–12).
4. Terminal clinical AIDS in the index case (OR 5.6; 95% CI 2.0–16) – this is likely to indicate a high viral load in the index case.

In UK HPA data from 1999 to 2018, no new cases of HIV infection were found after 8765 reported significant occupational exposures among HCWs [18]. The key studies informing our understanding of occupational seroconversion are summarized in Table 3 (Section 5.6.5).

### 5.6.4 | Mucocutaneous exposures or splash injuries

The risk of HIV acquisition from a mucocutaneous 'splash' injury (e.g. to the eye) is estimated to be around 0.1% (1 in 1000 exposures) if the HIV positive index case is not on ART, considerably lower than a percutaneous 'sharps' injury. Globally, in a systematic review and meta-analysis, eight cases of HIV transmission attributable to splash injuries were identified, almost always from a blood splash exposure rather than other bodily fluids [84].

HIV cannot be transmitted through intact skin. The risk of HIV transmission through nonintact skin (e.g. abrasions, cuts or sores) is considered to be negligible; to our knowledge, there have not been any reported case of HIV transmission through skin cuts or other forms of loss of skin integrity.

### 5.6.5 | Biting and spitting

In 2018, a systematic review was conducted to review the risk of HIV transmission through biting or spitting [74]. No cases of HIV transmission relating to spitting were identified, supporting the conclusion that there is no risk of HIV transmission from spitting. HCWs, emergency workers or members of the public can be fully reassured that there is no indication for PEP following spitting incidents. Nine cases of possible HIV transmission following biting episodes were identified in the systematic review. There was, however, considerable heterogeneity in the quality of the published literature. Poor-quality case reports included those in which: (1) the recipient had no documented HIV test at baseline; (2) the recipient had other significant potential risk factors for HIV transmission; (3) HIV seroconversion was reported to have occurred at a time interval incompatible with transmission secondary to the bite. In only three cases was the linked transmission confirmed by RNA sequencing and in total only

TABLE 3 Summary of evidence relating to HIV transmissions from occupational exposures

First author, year	Setting	Study type	Duration of follow-up	Number of occupational exposures	Number (%) of exposures where index case was HIV positive	Type of exposure	Other BBV	Received PEP	Number of HIV seroconversions
Li Hui, 2013 [21]	Australia	Case report	N/A	1	1 (100)	Sharps injury <sup>1</sup>	No	100%	1
Sin, 2016 [85]	Hong Kong	Retrospective cohort	12 months <sup>2</sup>	1525	50 (3.3)	Sharps 89% Splash 11%	HBV 7.4% HCV 1.6%	3.1%	None
Nwaiwu, 2017 [86]	USA	Prospective cohort	13 years	266	266 (100)	Sharps 53% Splash 43% Unknown 4%	No	21%	None
Rajkumar, 2014 [87]	India	Prospective cohort	6 months	356	8 (2.2)	Sharps 85% Splashes 15%	HBV 3.1%	None	None
Himmelreich, 2013 [88]	Germany	Prospective cohort	18 months	519	51/449 (11.4)	Sharps 100%	HCV 9.8% HBV 3.6%	No	None
Gupta, 2008 [89]	India	Prospective cohort	2 years	557	88 (16)	Sharps 81.1% Splash 18.8%	No	48% of 'high-risk' exposures	None
Cardo, 1997 [15]	USA	Case-control study	7 years	33	N/A	Sharps 100%	No	9%	33
Tomkins, 2002 [19]	Worldwide	Surveillance	1999–2002	Unknown	N/A	Unknown	No	100%	24 (6 definite cases and 18 possible)
Evans, 1999 [20]	Worldwide	Surveillance	1984–1999	Unknown	N/A	Sharps 89% Splash 8% Unknown 3%	No	Unknown	286 (95 definite <sup>3</sup> and 191 possible)
Woode, 2014 [18]	UK	Surveillance	2004–2013	4830	1270/4766 (30)	Sharps 71% Splash 29%	Known / possible HCV 54% HBV 9%	77%	None
Public Health England, 2020 [17]	UK	Surveillance	1997–2018	8,765	8,292 HIV positive / unknown HIV status	Unknown	Unknown	46%	None

BBV, blood-borne virus; HBV, hepatitis B virus; HCV, hepatitis C virus; NSI, needlestick injury; N/A, not applicable; PEP, post-exposure prophylaxis.

<sup>1</sup>Large volume inoculum from HIV positive index case with viraemia (> 100 000 copies/mL). Single-genome sequencing of plasma viral RNA identified 15 drug-susceptible transmitted/founder HIV genomes responsible for productive infection. Sequences emanating from these genomes exhibited extremely low diversity, suggesting virus sequestration as opposed to low-level replication as the cause of breakthrough infection.

<sup>2</sup>Only 6 months of follow-up if PEP not prescribed.

<sup>3</sup>Most (85/95; 89%) of the definite occupationally acquired HIV infections followed percutaneous exposure. Among the 10 remaining cases, eight were from mucocutaneous exposure and for two the exposure was not specified.

four cases of HIV transmission were thought to have plausibly resulted from a bite. In each case, the perpetrator had advanced HIV infection and was not on ART and was therefore likely to have high-level HIV viraemia. In three of the four cases, the bite resulted in a deep wound and the perpetrator had blood in their mouth at the time of the incident. In the fourth case, multiple bites were sustained from an HIV positive individual who was reported to have bleeding gums, but who had unknown HIV viral load and ART status; it was not reported whether the bites resulted in skin breakage. Considering these factors together, the review concluded that the overall risk of acquiring HIV from a bite by an HIV positive person is negligible, but the risk is increased by the presence of blood in the saliva plus a high viral load of the perpetrator plus deep wounds being inflicted [90].

## 5.7 | Risk of HIV transmission through injecting drug use

HIV and other blood-borne viruses (BBVs), including HBV and HCV, can be transmitted between PWID through the sharing of needles and other injecting equipment contaminated with infected blood [84, 91, 92]. In 2018, the prevalence of HIV among PWID who participated in the unlinked anonymous seroprevalence monitoring survey in England was low at 1.2% (95% CI 0.08%–1.6%) [93]. In 2018, there were 94 new HIV diagnoses which were likely to have been acquired through injecting drug use in the UK [94–96]. Overall, the number of people acquiring HIV through injecting drug use in the UK has been low since the early epidemic, except in the context of localized outbreaks. Although first identified in early 2015, an outbreak of HIV infection among PWID in Glasgow remained ongoing in 2019. Since its onset, over 150 individuals were diagnosed with HIV infection as part of that outbreak, related to transmission among a population who inject psychoactive drugs within Glasgow city centre. This population were often homeless, with high levels of involvement in the criminal justice system. Between 2011 and 2018, the HIV prevalence in PWID rose from 0.1% (95% CI 0–6%) to 4.8% (95% CI 3.4–6.2%) overall, and from 1.1% (95% CI 0.2–6.2%) to 10.8% (95% CI 7.4–15.5%) in Glasgow city centre [97]. This ongoing outbreak demonstrates that the availability of needle exchanges and opioid replacement therapy may be insufficient to prevent outbreaks in this vulnerable group, and PEP should be considered in a broader package of HIV prevention measures in PWID during an outbreak situation.

### 5.7.1 | Sexualized drug use

Sexualized drug use refers to the use of drugs in a sexual context. This includes 'chemsex', which describes the use of certain recreational drugs, particularly crystal methamphetamine, gamma hydroxybutyrate/gamma butyrolactone (GHB/GBL) and mephedrone, before or during planned sexual activity to sustain or enhance the experience [98, 99]. In a 2018 survey of 836 MSM attending sexual health clinics, 17% reported sexualized drug use in the last 6 months and 10% reported injecting ('slamming') chemsex drugs in the last 6 months [100], which leads to potential exposure to HIV and other BBVs. High levels of function in other aspects of life are often maintained and men may not self-identify as injecting drug users. Individuals who report drug use in a sexual context should therefore be asked about injecting and about sharing of equipment [101].

It is difficult to separate the risk of HIV transmission through sharing injecting equipment from the risk of HIV transmission from condomless anal sex. New PEP consultations are an ideal opportunity to identify those at risk and offer evidence-based interventions such as PrEP to reduce the risk of acquiring HIV.

## 6 | WHEN TO PRESCRIBE PEP

There is no evidence to inform the exact risk threshold at which PEP is indicated from an individual, population-level and cost-effectiveness perspective. The 2015 PEP guidelines suggested that if the risk of HIV transmission is  $> 1/1000$  then PEP is recommended, if it is between  $1/1000$  and  $1/10\ 000$  PEP should be considered and if it is  $< 1/10\ 000$  PEP is not recommended. These thresholds were not evidence-based so have been removed, but we recognize that they may assist services in making decisions on a case-by-case basis. In this latest iteration of the guidelines, we have included four categories which were informed by similar thresholds.

- **Recommended:** the benefits of PEP are likely to outweigh the risks, and PEP should be given unless there is a clear reason not to.
- **Consider:** the risk of HIV transmission is low, and the risk/benefit balance of PEP is less clear. The risk should be assessed on a case-by-case basis, taking into consideration factors shown in Box 1.
- **Generally not recommended:** the risk of HIV transmission is very low, and the potential toxicity and inconvenience of PEP are likely to outweigh the benefits unless there is a clear specific extenuating factor which increases the risk. We anticipate that PEP should very

rarely be given when the risk has been assessed and discussed. The risk here is generally  $< 1/10\ 000$ , but specific factors may increase the risk to  $> 1/10\ 000$ .

- **Not recommended:** the risk of HIV transmission is negligible and PEP should not be given.

## 6.1 | When to prescribe PEP following sexual exposure

We recommend the use of PEP following sexual exposure where there is a significant risk of HIV transmission.	1C
The risks and benefits of providing PEP for adolescents should be weighed carefully in the context of UK laws and judgements about autonomy in health care decision-making (e.g. Gillick competency), and balanced against protecting young people from harm.	GPP

A risk assessment and risk-benefit analysis should be undertaken for every individual presenting following an exposure and the decision to initiate PEP made on a case-by-case basis. This should consider the risk of the index case being HIV positive with a detectable viral load (Table 1, **Section 5.3.1**), the risk of transmission according to exposure (Table 2, **Section 5.4.1**) and the ART status and viral load of the index case, if known. Where the index case is known to be HIV positive but not virologically suppressed, it is important to ascertain if they have experienced prior virological failure and/or have known drug resistance mutations. The recommendations for PEP with sexual exposure are summarized in Table 4 (**Section 6.5**). Awareness of the local HIV seroprevalence in the index partner should be factored into local protocols.

The risk calculation/assessments for an adolescent following sexual or occupational exposure should be the same as those for an adult. A decision on whether to offer PEP should be made in the same way. The decision about whether to complete the decision-making process and/or provide PEP with or without involvement of the parent or guardian should be made in the context of UK laws and judgements about autonomy in health care decision-making (e.g. Gillick competency), and balanced against protecting young people from harm.

### 6.1.1 | Index partner is of unknown HIV status

Proactive attempts should be made to establish the HIV status of the index partner; this should not, however, delay initiation of PEP where indicated (Table 4).	1C
--	----

Proactive attempts should be made to establish the HIV status of the index partner whilst not delaying PEP initiation where indicated. If the index partner is from a risk group or country of high HIV prevalence (prevalence  $> 1\%$ ) and is not known to be on suppressive ART, then PEP is routinely recommended following receptive anal sex (see Table 4, **Section 6.5**).

### 6.1.2 | Index partner known to be HIV positive

Attempts should be made at the earliest opportunity to determine the plasma HIV viral load, resistance profile and treatment history of the index partner	GPP
PEP is not recommended if the index partner has been on ART for at least 6 months with an undetectable plasma HIV viral load (at the time of last measurement and within the last 6 months) and with good reported adherence.	1A
Individuals should be encouraged to undergo a formal PEP assessment and verification of index partner's HIV details even when they believe the partner has an undetectable HIV viral load.	GPP
If there are any doubts about the ART history, the index partner's adherence to ART or the viral load, then PEP should be given following condomless receptive anal intercourse.	GPP

In the setting where the individual is known to be HIV positive and known not to be on suppressive ART, the risk per exposure can be calculated by multiplying the risk that source is HIV positive with a detectable HIV viral load (i.e. 1) and the risk per exposure (Table 2, **Section 5.4.1**):

*Risk of HIV transmission = risk that source is HIV positive with a detectable HIV viral load  $\times$  risk per exposure*

For example, if a man presents for PEP following condomless receptive anal intercourse with ejaculation with an HIV positive male partner who is not on ART:

*Risk of HIV transmission =  $1 \times 1/65 = 1/65 = 0.015$  (or 1.5%)*

If the index partner is known to be HIV positive, attempts should be made at the earliest opportunity to determine the HIV viral load, resistance profile and treatment history to determine if PEP is required and which regimen should be used in the context of detectable viraemia and the potential for drug resistance. Both an RCT and observational studies have confirmed that individuals on suppressive ART cannot transmit HIV sexually regardless of sexual orientation [49, 51, 102-105]. In light of this, PEP is not recommended for any kind of condomless sex with an HIV positive person who has been on ART for at least 6 months with an undetectable HIV viral load (at the time of last

TABLE 4 Summary table of post-exposure prophylaxis (PEP) prescribing recommendations

	Index HIV positive		Index of unknown HIV status	
	HIV VL unknown or detectable	HIV VL undetectable	From high-prevalence country/high-risk group (e.g. MSM) <sup>a</sup>	From low-prevalence country/group
<b>Sexual exposures</b>				
Receptive anal sex	Recommended	Not recommended <sup>b</sup>	Recommended	Not recommended
Insertive anal sex	Recommended	Not recommended <sup>b</sup>	Consider <sup>c,d</sup>	Not recommended
Receptive vaginal sex	Recommended	Not recommended <sup>b</sup>	Generally not recommended <sup>c,d</sup>	Not recommended
Insertive vaginal sex	Consider <sup>c</sup>	Not recommended	Generally not recommended <sup>c,d</sup>	Not recommended
Fellatio with ejaculation	Not recommended	Not recommended	Not recommended	Not recommended
Fellatio without ejaculation	Not recommended	Not recommended	Not recommended	Not recommended
Splash of semen into eye	Not recommended	Not recommended	Not recommended	Not recommended
Cunnilingus	Not recommended	Not recommended	Not recommended	Not recommended
<b>Occupational and other exposures</b>				
Sharing of injecting equipment	Recommended	Not recommended <sup>b</sup>	Generally not recommended <sup>e</sup>	Not recommended
Sharps injury	Recommended	Not recommended <sup>b</sup>	Generally not recommended <sup>c,e,f</sup>	Not recommended
Mucosal splash injury	Recommended	Not recommended <sup>b</sup>	Generally not recommended <sup>c</sup>	Not recommended
Human bite	Generally not recommended <sup>g</sup>	Not recommended	Not recommended	Not recommended
Needlestick from a discarded needle in the community			Not recommended	Not recommended

**Recommended:** the benefits of PEP are likely to outweigh the risks; PEP should be given unless there is a clear reason not to.

**Consider:** the risk of HIV transmission is low; the risk/benefit balance of PEP is less clear. The risk should be assessed on a case-by-case basis taking into consideration factors shown in footnotes c and d below.

**Generally not recommended:** the risk of HIV transmission is very low; the potential toxicity and inconvenience of PEP are likely to outweigh the benefit unless there is a clear specific extenuating factor which increases the risk (see footnotes c, d, e and f below). We anticipate that PEP should very rarely be given when the risk has been assessed and discussed (Sections 6.1.2 and 6.2.1.2).

**Not recommended:** the risk of HIV transmission is negligible and PEP should not be given.

MSM, men who have sex with men; VL, viral load.

<sup>a</sup>High-prevalence countries or high-risk groups are those where there is a significant likelihood of the index case individual being HIV positive. Within the UK at present, this is likely to be men who have sex with men (MSM), people who inject drugs from high-risk countries (see d below) and individuals who have immigrated to the UK from areas of high HIV prevalence, particularly sub-Saharan Africa (high prevalence is > 1%). Country-specific HIV prevalence can be found at <https://aidsinfo.unaids.org>

<sup>b</sup>The index case has been on antiretroviral therapy (ART) for at least 6 months with an undetectable plasma HIV viral load (at the time of last measurement and within the last 6 months) with good reported adherence. Where there is any uncertainty about HIV viral load (VL) results or adherence to ART, then PEP should be given. The VL threshold considered 'undetectable' in the PARTNER1 and PARTNER2 and HPTN052 studies was < 200 copies/mL.

<sup>c</sup>Factors that influence decision-making in all exposures: more detailed knowledge of local HIV prevalence within the index case subpopulation<sup>a</sup>. The recommendations relate to high-risk groups living in the UK (based on the known prevalence of detectable HIV viraemia in the UK, see Table 1). Where the index case is from a high-risk group and normally resides outside the UK, the risk may be greater and where there is doubt PEP should be given.

<sup>d</sup>Factors that may influence decision-making included in sexual exposures: (1) breaches in the mucosal barrier such as genital ulcer disease and anal or vaginal trauma following sexual assault or first intercourse; (2) multiple episodes of exposure within a short period of time, e.g. group sex; (3) sexually transmitted infection in either partner; (4) individuals at higher risk of acquiring HIV, e.g. transgender.

<sup>e</sup>HIV prevalence amongst injecting drug users (IDUs) varies considerably depending on whether there is a local outbreak and country of origin and is particularly high in IDUs from Eastern Europe and central Asia. Region-specific estimates can be found in the Joint United Nations Programme on HIV/AIDS (UNAIDS) Gap Report ([http://www.unaids.org/sites/default/files/media\\_asset/05\\_Peoplewhoinjectdrugs.pdf](http://www.unaids.org/sites/default/files/media_asset/05_Peoplewhoinjectdrugs.pdf)).

<sup>f</sup>Factors that may influence decision-making include in occupational exposures: deep trauma or bolus of blood injected.

<sup>g</sup>PEP should only be considered after a bite if all three criteria are met: (a) the biter's saliva was visibly contaminated with blood; (b) the biter is known or suspected to have a plasma HIV VL > 3.0 log copies/mL; and (c) the bite has resulted in severe and/or deep tissue injuries.

measurement and within the previous 6 months) and reported good adherence (see Table 4, 1A). If there is any doubt about the index partner's viral load or adherence to ART, then PEP should be given as a precaution following condomless anal intercourse.

PEP is 'not recommended' following fellatio with ejaculation as the risk is estimated to be very low at  $< 1/10\ 000$  (2C). A cohort study demonstrated that, after an estimated total of over 19 000 condomless orogenital exposures with an HIV positive partner, no HIV seroconversions occurred [67]. A modelling study from 1999 estimated an upper limit of risk of  $4/10\ 000$  [54]. There was only one single transmission pair (confirmed by sequencing), where both individuals independently reported only orogenital contact [106]. Other case reports of unproven linked orogenital transmission featured dental procedures, pharyngitis, chemotherapy and periodontal diseases as additional risk factors [107]. In extreme circumstances, such as primary HIV infection and oropharyngeal trauma/ulceration, PEP can be considered, but in general PEP is not recommended. PEP is also not recommended following semen splash in the eye as the risk is negligible with no documented HIV transmissions via this route (GPP).

Following insertive vaginal intercourse with an HIV positive partner not on ART, PEP should be 'considered' rather than routinely 'recommended' as the risk is  $< 1/1219$  [56, 57, 61] (2C). Again, the presence of additional factors in Box 1 (Section 5.5) should be reviewed and clinician discretion applied.

### 6.1.3 | Sexual assault

There is concern (though no published evidence) that transmission of HIV is likely to be increased as a result of any trauma following aggravated sexual intercourse (anal or vaginal). Clinicians may therefore consider recommending PEP more readily in such situations, particularly if the assailant is from a high-prevalence group [108]. If the assailant is from a low-prevalence group in the UK, after the balance of risks and benefits has been discussed with the patient, it is likely that PEP provision will generally not be indicated.

### 6.1.4 | Commercial sex workers

HIV prevalence among female sex workers varies by region. It has remained low in Western Europe ( $< 1\%$ ) and Central Europe (1–2%) but is higher in Eastern Europe, ranging between 2.5% and 8% [109]. HIV prevalence is

highest in sex workers who inject drugs [109]. HIV prevalence among male sex workers, reported from 27 countries, was 14% [110]. The formula in Section 5.5 can be used to determine the risk of HIV transmission.

## 6.2 | When to prescribe following occupational exposures

### 6.2.1 | Sharps and mucosal splash injuries

#### *HIV positive index case*

PEP is recommended following a high-risk injury (sharps or mucosal splash) if the index case is known to be HIV positive and has not been on ART for $> 6$ months with a suppressed viral load within the last 6 months.	1C
--	----

PEP is generally not indicated following a sharps injury if the index case has been on ART for at least 6 months with an undetectable HIV viral load (at the time of last measurement and within the previous 6 months) and reported good adherence (see Table 4, 1A). However, in view of the lack of direct evidence, a case-by-case decision can be made depending on the nature of the injury.	2C
--	----

PEP is not recommended following a splash injury if the index case is known to have a sustained undetectable viral load.	1C
--	----

PEP is not recommended where there is no or negligible risk of HIV transmission, e.g. through intact skin that comes into contact with HIV-infected blood or other bodily fluids.	1C
---	----

The extensive data informing elimination of transmission risk with suppressive ART only applies to sexual exposures. In the context of sharps and mucocutaneous splash injuries, the transmission risk when the index is on suppressive ART is likely to be negligible. PEP is not recommended following any splash injury where the index case has been on ART for at least 6 months with an undetectable plasma HIV viral load (at the time of last measurement and within the last 6 months) with good reported adherence, but can be considered if there is a blood splash to a mucosal surface and the index case is not known to have an undetectable viral load. Although it is highly likely that viral suppression eliminates the risk of HIV transmission through sharps injuries, the lack of evidence to support this should be discussed, and a case-by-case decision can be made in the context of high-risk sharps injuries. Where there are concerns about the viral load of the index case being detectable, or concerns around ART adherence or if the injury is particularly high risk (e.g. deep wound with hollow bore needle), then PEP could be considered.

### Index case of unknown HIV status

PEP is not recommended following a sharps or mucosal splash injury if the index case is untested but from a low-risk group (Table 4).	1C
PEP is generally not recommended following a sharps or mucosal splash injury if the index case is untested and from a high-risk group (e.g. MSM or PWID), unless there were other factors that increased the likelihood of transmission (e.g. a deep injury or blood bolus injected or a sharps injury from a PWID in the context of a local outbreak) (see Table 4).	1C
All efforts should be made to seek prompt voluntary HIV testing of the index case.	1C
Index case HIV testing should not delay PEP initiation where indicated.	GPP
If the index case is unable to give informed consent for HIV testing (e.g. unconscious or altered mental status), then HIV testing can be performed if it is in the best medical interest of the index case.	GPP

When deciding whether PEP is indicated where the HIV status of the index case is unknown and not obtainable or pending the HIV test result, the probability of the index case being HIV positive must be estimated from Table 1 (**Section 5.3.1**), or if the index case is of non-UK origin, using this link: <https://aidsinfo.unaids.org>. The equation described in **Section 5.5** and shown below can be used to calculate the risk of HIV transmission from the incident.

Risk of HIV transmission = risk that source is HIV positive with a detectable HIV viral load × risk per exposure\*

\*1/333 for needle stick injury

\*1/1000 for splash injury

For example, a woman of British origin has a prevalence of detectable HIV viraemia of 0.1 in 1000 or 1/10 000 (Table 1, Section 5.3.1), which when multiplied by the risk of transmission from a needle stick injury (1/333) gives a transmission risk from the incident of:  $1/10\ 000 \times 1/333 = 0.000003$  or 1/3 333 333. So, in the above example of a needlestick from a British woman of unknown HIV status, PEP would not be recommended as the risk is negligible.

Conversely, in the example of a needlestick from an MSM in London, the probability of the index case being HIV positive with a detectable viral load is 32/1000, which multiplied by the transmission risk of 1/333, gives a risk of HIV transmission of:  $32/1000 \times 1/333 = 32/333\ 000 = 1/10\ 405$  (or 0.01%). This risk is also extremely small, so PEP would generally not be recommended unless there were other factors that increased the likelihood of transmission, such as an inoculum of blood having been injected. In the case of an uncomplicated needlestick injury from an untested MSM, the extremely small risk of HIV transmission along with the potential toxicity and inconvenience of PEP

should be directly discussed with the individual. We anticipate that, in most cases following a risk assessment and discussion of the risks and benefits, PEP would generally not be given. However, the decision must be made on a case-by-case basis using clinician discretion and taking into account the preferences of the attendee.

### 6.2.2 | Needlestick injuries in the community

PEP is not recommended following a community needlestick exposure. 2D

In general, PEP is not recommended following a community needlestick exposure as the risk is extremely low [111] and it is usually not possible to determine: (1) whether the needle has been used and for what purpose; (2) the HIV status of the index case, and (3) the interval between the needle use and the exposure. Whilst there have been a handful of cases of HBV and HCV transmission from community needlesticks, there have been no reported cases of HIV transmission. The maximum potential risk of transmission from a needlestick injury from a freshly discarded needle in the community can be calculated using regional HIV prevalence data (Table 1, **Section 5.3.1**) and the following formula:

Risk of HIV transmission = risk that source is HIV positive with a detectable viral load × 0.3 (risk per exposure)

However, once blood has dried, HIV becomes nonviable within a couple of hours; in studies where only small amounts of blood are in the syringe, viable HIV cannot be detected after 24 h [112]. Therefore, this formula should only be used, and PEP considered following a community needlestick injury, if the recipient is confident that it was a freshly discarded needle.

### 6.3 | Human bites

In general, PEP is not recommended following a bite as, although the precise risk of transmission is unknown, it is likely to be negligible. 2D

However, PEP could be considered for patients who fulfil ALL of the following three criteria: 2D

- the biter's saliva was visibly contaminated with blood;
- the biter is known or suspected to have a plasma HIV viral load > 3.0 log copies/mL; and
- the bite has resulted in severe and/or deep tissue injuries.

Further information on the evidence that supported this recommendation can be found in **Section 5.6.6** and guidance

regarding the management of human bites is available at: <http://cks.nice.org.uk/bites-human-and-animal#!scenario:1>

## 6.4 | People who inject drugs

As described in Section 5.7, overall the number of people acquiring HIV through injecting drug use in the UK has been low since the early epidemic, except in the context of localized outbreaks.

Individuals who report the use of any injectable drugs should be asked specifically if they are currently injecting and, if so, whether the equipment is ever shared.	GPP
The HIV status and, if positive, viral load and ART history of their injecting partners should be ascertained.	GPP
PEP is recommended for PWID after sharing needles/equipment if their index injecting partner is HIV positive and not on ART for > 6 months with a suppressed viral load.	1C
PEP is generally not recommended in PWID after sharing needles/equipment with an injecting partner of unknown HIV status from a high-prevalence country/high-risk group, but PEP can be considered on a case-by-case basis for PWID in the context of a localized outbreak.	GPP
Existing harm-reduction strategies such as needle exchange and opiate substitution programmes should be encouraged for PWID.	1D
MSM should be specifically asked about chemsex and injecting drug use.	2D

## 7 | WHAT TO PRESCRIBE FOR PEP

### 7.1 | First-lines

We recommend the use of TD 245 mg/FTC 200 mg and raltegravir 1200 mg once daily as the regimen of choice for PEP (Table 5).	1B
If there is evidence that the index case has a current or past history of ART failure, expert advice should be sought as to whether the PEP regimen should be modified in relation to ART history and/or resistance testing.	1D
For women who are pregnant, raltegravir 400 mg twice daily is preferred (with TD 245 mg/FTC 200 mg). Where accessing raltegravir 400 mg might cause delay, we recommend using raltegravir 600 mg twice daily and switching at the earliest opportunity.	1D

In established HIV infection, combination therapy with at least three medications from two medication classes is

recommended for initial therapy. It is thus recommended to use a triple agent regimen for PEP (1D), although some international guidelines do recommend dual-class regimens in selected situations [113, 114]. Simplification to two drugs could be considered in select rare situations if continuing a third agent is not possible.

### 7.1.1 | Nucleoside reverse transcriptase inhibitors (NRTIs)

FTC and TD are recommended as the NRTI backbone based on efficacy, tolerability, safety and convenience. Although most PEP and PrEP studies have used tenofovir disoproxil fumarate (TDF), generic TD is often formulated as a nonfumarate salt; as all approved salt formulations have demonstrated bioequivalence to TDF they are interchangeable. Tenofovir and FTC demonstrate good genital tract and rectal tissue penetration in animal models (reaching peak levels within 24 h of dosing and maintaining high levels for up to 7 days) [13] and good male and female genital tract penetration, including the rectal compartment, in human studies [115]; these characteristics may be advantageous for PrEP and PEP [13]. Phase 3 PrEP studies have demonstrated high efficacy rates for TDF alone and TDF/FTC in high-risk heterosexuals and MSM [116–119]. A 2015 systematic review of antiretroviral drugs for PEP concluded that TD-based regimens have better completion rates than zidovudine-based regimens (78% versus 59%, respectively) and the rate of PEP discontinuation because of an adverse event was lower among people taking TD-based PEP (0.3%; 95% CI 0–1.1%) vs a zidovudine-based regimen (3.2%; 95% CI 1.5–4.9%) [120].

Tenofovir alafenamide (TAF) is a tenofovir prodrug and is considered a safer alternative than TD in patients with chronic kidney disease and could be used where the baseline estimated glomerular filtration rate (eGFR) is < 50 mL/min. Currently, there are no in-human data on the use of TAF for PEP; however, in combination with FTC, TAF was at least as effective as TD in a large PrEP trial in MSM [121], while data in women are not available.

TD/FTC is generally well tolerated in practice; however, very common side effects ( $\geq 1/10$ ) include headache, dizziness, diarrhoea and nausea, and common side effects ( $\geq 1/100$  to < 1/10) include insomnia and abdominal pain [122]. These side effects are usually mild, transient and rarely treatment-limiting. TD is associated with renal toxicity and, although this is usually not clinically important in the context of short-course prescribing for PEP, individuals should undergo baseline assessment of renal function and an alternative NRTI backbone should be prescribed when the calculated creatinine clearance is below 50 mL/min (see Table 5, **Section 7.1.3**).



### 7.1.2 | Integrase strand transfer inhibitors (INSTIs)

INSTIs are well tolerated and have all demonstrated at least noninferior efficacy compared with NNRTIs and PIs [123-125] in the context of triple therapy for HIV treatment. Raltegravir, elvitegravir and dolutegravir have been widely used in the UK. Bictegravir was licensed in the UK in June 2018. Elvitegravir requires co-administration with cobicistat, a pharmacokinetic booster with a similar drug–drug interaction profile to ritonavir. A 600-mg tablet of raltegravir was licensed in the UK in 2017, facilitating a 1200 mg once-daily dosing regimen. Unfortunately, the 600-mg tablets are more hygroscopic and currently the summary of product characteristics (SPC) specifies that they must be stored in their original packaging – a sealed water-tight container with moisture absorbent – as stability data for nonoriginal packaging are awaited. Therefore, at this point in time, 5-day starter packs containing 600-mg raltegravir tablets cannot be produced and the minimum duration that can be dispensed is 30 days. Once-daily raltegravir 1200 mg remains the preferred third agent where the full 28-day PEP course is given at the initial attendance. We recommend a cessation of starter pack use where possible for the reasons outlined in Section 9.2. In services where PEP must be initiated with a 5-day starter pack, and if stability data for raltegravir 600 mg in nonoriginal packaging remain unavailable, then raltegravir 400 mg twice daily is the preferred third agent.

The most common clinical adverse events reported with INSTIs are diarrhoea, nausea and headache. Suicidal ideation or behaviour is an uncommonly reported side effect of dolutegravir, particularly in patients with a pre-existing history of depression or psychiatric illness [126]. INSTIs are better tolerated than PIs and rates of INSTI resistance in the UK are low (**Section 4.2.3**).

This decision to use raltegravir 1200 mg as the preferred third agent was made as a result of a number of considerations: (1) concern about neural tube defects (NTDs) in women at risk of pregnancy which would complicate the counselling process for PEP providers, (2) cost, and (3) good tolerability data from a UK observational study [127]. The optimal regimen will be reviewed at the time of the next guideline update.

**Raltegravir:** Observational studies assessing raltegravir/FTC/tenofovir as PEP in MSM concluded that it is well tolerated and results in high levels of adherence [128-130]. A PEP RCT showed that tenofovir/FTC plus raltegravir 400 mg twice daily was better tolerated than tenofovir/FTC plus lopinavir/ritonavir [131]. Recent data on raltegravir 1200 mg once daily (with tenofovir 245 mg/FTC 200 mg) as PEP for 143 adults in Belfast demonstrated the regimen to be well tolerated, with 123/143 (87%) reporting no side effects. Amongst the 19/143 (13%) who reported side effects,

headache, diarrhoea and nausea were the most common. One person reported poor sleep and suicidal ideation. There were no serious laboratory adverse events. No HIV seroconversions were reported amongst those (109/143; 76%) who attended for follow-up HIV blood testing (127).

**Elvitegravir:** Three PEP studies of elvitegravir/cobicistat in combination with tenofovir (disoproxil or alafenamide)/FTC including over 400 individuals demonstrated high completion rates and good tolerability. One seroconversion was observed in an individual with multiple exposures before and after PEP [28]. Elvitegravir/cobicistat in combination with a tenofovir/FTC backbone is a single-tablet regime option for PEP but is limited by the risk of drug–drug interactions as a result of the boosting agent cobicistat.

**Dolutegravir:** One open-label, single-arm study at three sexual health clinics and two emergency departments in Australia followed up 100 HIV-negative MSM requiring PEP who received dolutegravir and tenofovir/FTC for 28 days [132]. No participants acquired HIV through week 12. The most common clinical adverse events were fatigue (26%), nausea (25%), diarrhoea (21%) and headache (10%). Dolutegravir with tenofovir/FTC is a safe and reasonably well-tolerated option for once-daily PEP. There is a BHIVA statement on a potential safety signal relating to NTDs in infants born to women conceiving on dolutegravir in Botswana, and this is discussed further in **Section 10.2**. (<https://www.bhiva.org/BHIVA-statement-on-safety-signal-in-infants-born-to-mothers-conceiving-on-dolutegravir>, accessed 13/02/2020).

**Bictegravir:** There are no data available to support the use of bictegravir-based PEP.

## 7.2 | Alternative regimens

### 7.2.1 | Nonnucleoside reverse transcriptase inhibitors (NNRTIs)

The prevalence of NNRTI resistance in the UK is significant (4.2% in 2016) and thus NNRTIs are not routinely recommended for use in PEP.

### 7.2.2 | Protease inhibitors (PIs)

PIs are potent inhibitors of the cytochrome P450 system (CYP3A4), markedly increasing levels of some drugs metabolized through the same pathway, including some corticosteroids, recreational drugs (<https://www.hiv-druginteractions.org/checker>), antibiotics and antipsychotics amongst others. One study reports high levels of recreational drug use among MSM genitourinary medicine attendees, an additional interaction concern [133].

**TABLE 5** Recommended combinations for post-exposure prophylaxis (PEP)

	NRTI backbone (2 medications)	Third agent
Recommended combination	Tenofovir disoproxil 245 mg, emtricitabine 200 mg, <sup>a</sup> one tablet once daily	Raltegravir 1200 mg once daily <sup>b,c</sup>
Alternative 1	eGFR <sup>e</sup> 30–50 mL/min: Descovy <sup>f</sup> : 25 mg, one tablet once daily eGFR <sup>d</sup> < 30 mL/min: seek expert advice from infectious diseases/GUM/sexual health team	<u>Integrase inhibitors</u> Raltegravir 400 mg twice daily <sup>b</sup> OR Dolutegravir 50 mg, one tablet once daily <sup>b,d</sup> <u>Protease inhibitors</u> Darunavir 800 mg + ritonavir 100 mg <sup>g</sup> once daily OR Atazanavir 300 mg + ritonavir 100 mg <sup>g</sup> once daily
Alternative 2	Elvitegravir 150 mg/cobicistat 150 mg/tenofovir-DF 245 mg/emtricitabine 200 mg FDC: one tablet once daily <sup>g</sup> If eGFR 30–70 mL/min elvitegravir 150 mg/cobicistat 150 mg/tenofovir-AF 10 mg/emtricitabine 200 mg FDC	

Swallowing difficulty: tenofovir/emtricitabine can be dissolved in 100 mL of water or orange juice and taken immediately. Lopinavir/ritonavir can be used as an alternative to dolutegravir and is commercially available as an oral solution; the recommended dosage is 5 mL twice daily with food. Where liquid formulations are unavailable, dolutegravir tablets may be split or crushed and added to a small amount of semi-solid food or liquid, all of which should be consumed immediately.

eGFR, estimated glomerular filtration rate; FDC, fixed-dose combination; GUM, genitourinary medicine; NRTI, nucleoside reverse transcriptase inhibitor.

<sup>a</sup>Tenofovir disoproxil 245 mg/emtricitabine 200 mg FDC is the preferred agent in chronic hepatitis B virus infection.

<sup>b</sup>Antacids and multivitamins (products containing metal cations, e.g. magnesium/aluminium, which can chelate and reduce the absorption of INSTIs) should be avoided where possible during PEP with once-daily raltegravir; see Appendix A. An alternative noninteracting medication may be considered. Metal cation-containing medicines must be separated by at least 4 h from twice-daily raltegravir and dolutegravir. See Appendix A for other drug–drug interactions including rifampicin.

<sup>c</sup>For women who are pregnant, raltegravir 400 mg twice daily is preferred as the third agent. Where accessing raltegravir 400 mg might cause delay, we recommend using raltegravir 600 mg twice daily and switching at the earliest opportunity.

<sup>d</sup>For women who are at risk of pregnancy or under 6 weeks pregnant, we recommend avoiding the use of dolutegravir. For women who are more than 6 weeks pregnant, dolutegravir-based PEP can be used.

<sup>e</sup>eGFR should ideally be calculated using the Cockcroft Gault method.

<sup>f</sup>Tenofovir alafenamide/emtricitabine (Descovy) may be preferred to tenofovir disoproxil fumarate 245 mg/emtricitabine 200 mg in patients with abnormal renal function at baseline. The dose of Descovy depends on the third agent chosen: Descovy 200 mg/25 mg should be prescribed with dolutegravir or raltegravir. Descovy 200 mg/10 mg should be prescribed with the protease inhibitors darunavir/ritonavir and atazanavir/ritonavir. Note that Descovy is more susceptible to drug interactions when combined with enzyme inducers; conduct thorough drug interaction check or seek specialist advice.

<sup>g</sup>Significant drug–drug interactions can occur with boosted protease inhibitors and elvitegravir/cobicistat; seek expert advice from an HIV specialist pharmacist, local medicines and poisons information centre or use the website [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)

Darunavir/ritonavir (DRV/r) has been compared to lopinavir/ritonavir (LPV/r); the percentage with early discontinuation and adverse drug reactions was 6.5% and 68% in the DRV/r arm versus 10.0% and 75% in the LPV/r arm, respectively, these differences being nonsignificant. Fewer of the DRV/r-receiving participants (16.1%) had at least one grade 2 or 3 adverse drug reaction compared with those receiving LPV/r (29.3%) ( $P = 0.006$ ). No HIV seroconversions were reported during follow-up [134].

Atazanavir/ritonavir when compared to LPV/r with zidovudine/lamivudine as PEP had a similar rate of discontinuation, with almost half of participants experiencing side effects in both arms [135, 136].

### 7.2.3 | C-C chemokine receptor type 5 (CCR5) antagonists

Maraviroc (MVC) is well tolerated and reaches very high levels in genital tract tissues, so its utility for PEP is being

investigated. Two RCTs have concluded that a PEP regimen of Truvada (Gilead, Foster City, CA, USA) plus MVC is better tolerated than Truvada plus LPV/r [131, 137] but as MVC-based ART is not recommended as first-line HIV treatment [138] and there is a possibility that non-CCR5-tropic virus can be transmitted, MVC-based PEP is not recommended [139].

## 7.3 | Side effects

Where an individual reports significant current or previous intolerance to one or more PEP agents, an alternative agent(s) should be considered.	2D
--	----

Raltegravir with TD/FTC as a PEP regime is generally well tolerated and routine provision of anti-emetics and anti-diarrhoeals is not recommended. Where anti-emetics are provided, domperidone should not be used with PIs because of a significant drug–drug interaction with ritonavir [140].

Where any individual has experienced treatment-limiting tolerability or toxicity issues on prior PEP, an alternative regimen should be prescribed depending on the availability of other medication and on the nature and severity of the adverse event(s). Where prior adverse events were not serious and alternative PEP agents are not readily available (e.g. out of hours in an emergency department setting), then PEP should not be delayed and switch should be considered when practicable.

Although proximal renal tubular dysfunction and Fanconi's syndrome have been reported in HIV positive individuals on tenofovir-based ART, these have not been reported in the setting of PEP or PrEP to date [117]. The most common laboratory adverse event reported in the context of PEP was mildly raised alanine aminotransferase (22%), but there were no cases of clinical hepatitis [126].

Myopathy or rhabdomyolysis has been reported with INSTIs [141, 142] and therefore caution should be taken in individuals with a history of myopathy or who are using other medicinal products associated with these conditions, for example statins [143].

## 7.4 | Drug–drug interactions

An accurate verified medication history should be obtained, including the use of over-the-counter medication, vitamins/minerals, herbal remedies and recreational drugs, before PEP is prescribed to ensure that no significant drug–drug interactions are present.	1D
---	----

We recommend that potential drug–drug interactions are checked using the SPC and/or the Liverpool University drug interaction website (<https://www.hiv-druginteractions.org/checker>) but summarize some key drug–drug interactions here and in Appendix A. Boosted drugs (PIs and elvitegravir) are associated with numerous drug–drug interactions, for example with several steroids (including intranasal and inhaled steroids) and statins (risk of rhabdomyolysis, particularly with simvastatin).

**Cations:** Although raltegravir and dolutegravir pose a low risk for drug–drug interactions, raltegravir binds to divalent cations such as iron, aluminium, magnesium and calcium and forms a complex at the level of the gastrointestinal tract which results in less raltegravir being absorbed. Drug–drug interaction studies with antacids containing divalent cations have shown a more pronounced reduction in raltegravir minimum concentration ( $C_{min}$ ) when raltegravir was administered once daily compared to a twice-daily regimen [144]. A similar effect for iron supplements cannot be excluded. Therefore, concomitant use of metal cation containing antacids, iron supplements and multivitamins should ideally be avoided

with once-daily raltegravir or should be separated by at least 4 h from twice-daily raltegravir 400 mg [144]. Switch to a non-cation-containing acid-reducing agent is recommended during INSTI-based PEP if clinically indicated and nonessential mineral supplements should be stopped.

**Rifampicin:** Rifampicin is contraindicated with boosted drugs (PIs and elvitegravir). Raltegravir and dolutegravir require dose adjustment to 800 mg twice daily and 50 mg twice daily, respectively.

**TAF/FTC:** The interaction profile of TAF (**Descovy**<sup>®</sup>) (Gilead, Foster City, CA, USA) is significantly different from that of TD/FTC (see Appendix A for further details).

## 8 | TIMING AND DURATION OF PEP

PEP should be initiated as soon as possible after exposure, preferably within 24 h, but can be considered up to 72 h.	1D
We do not recommend initiating PEP beyond 72 h after exposure.	1D
The duration of PEP should be 28 days.	1D

Animal studies show that earlier initiation of PEP is more effective than later initiation; in one study, the efficacy of PEP was greater when initiated 12 and 36 h after exposure compared to 72 h after exposure [12]. In a second study, efficacy was greater when PEP was initiated 24 h after exposure rather than 48 or 72 h after exposure [11]. A maximum 72-h window is further supported by an intrarectal simian immunodeficiency virus (SIV) inoculum study in rhesus monkeys where ART was initiated on day 3 post exposure; this blocked the emergence of viral RNA and proviral DNA in peripheral blood, lymph nodes and the gastrointestinal tract but, on discontinuation of ART after 24 weeks, all animals experienced viral rebound [145].

We therefore recommend that it is essential to initiate PEP as soon as possible after exposure, preferably within a matter of hours, but it can be considered up to 72 h. The attendee should be informed that the earlier the initiation of PEP, the more efficacious, and that delay in initiation diminishes efficacy. In addition, complete adherence to PEP regimens should be emphasized, especially considering that this healthy population may not be accustomed to taking medication regularly.

In a retrospective review where 649 people were prescribed PEP for sexual exposures, the mean time from exposure to first PEP medication dose was 38.5 h [33]. A total of 69% completed the 4–6 week follow-up visit, 44% completed the 3-month visit, and 24% completed a 6-month visit. There were a total of seven seroconversions among PEP users within the study period. The mean time from exposure to

first PEP medication dose was 51.5 h for people who seroconverted. However, it is unclear whether there were further exposures following PEP as the follow-up period included HIV testing 6 months after the initial exposure.

The optimal duration of PEP is unknown. However, animal studies and case-controlled studies in HCWs suggest that the effectiveness of PEP declines if < 28 days is used. All of the macaques treated for 28 days with PEP (9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) following intravenous inoculation of SIV within the prior 24 h) were protected from infection, compared to half of the macaques treated for 10 days with PEP, and none of those treated with 3 days of PEP [11]; in the absence of better quality data showing that PEP is effective with a shorter duration, we recommend a duration of a minimum of 28 days. As a consequence of the fact that the raltegravir 600-mg tablets are more hygroscopic, the current SPC mandates that they must be stored in their original packaging – a sealed water-tight container with moisture absorbent containing 30 days of medication. As many antiretroviral agents are produced in 30-day packs, the provision of a 30-day pack minimizes the amount of manipulation required by pharmacists, which is potentially more cost-effective.

## 9 | HOW TO PROVIDE HIV PEP

For PEP to be maximally effective, a 24-h service is recommended.	1C
It is recommended that local policies include 24-h access to advice from an experienced HIV clinician, particularly for complex cases.	1D

For PEP to be maximally effective, all-year-round 24-h access should be available. Local policies and pathways must be established to enable this within a geographical network. Emergency medicine and urgent care providers will therefore be expected to assume significant responsibility for out-of-hours PEP provision. Necessary support and training should be provided by local departments with expertise, such as occupational health, genitourinary (GU) medicine, HIV medicine, sexual and reproductive health clinicians, infectious diseases or virology/microbiology departments. The training issues are essentially those outlined comprehensively in the Department of Health/EAGA guidance on HIV PEP [1, 146].

Individuals receiving PEP from an emergency or urgent care service should be seen as early as possible by either their occupational health department or local sexual health clinic. PEP should not be withheld until such expertise is available. For occupational exposures, the occupational health service has the responsibility for the testing of the index case in conjunction with the attending

practitioner and according to local policy which define roles and responsibilities, advice to the PEP user during the course and the follow-up blood testing.

### 9.1 | Baseline risk assessment

It is essential that an appropriate risk assessment for both sexual and occupational exposures be performed to enable provision of PEP according to the recommendations, as outlined in Sections 5–7 and summarized in Table 4 (Section 6.5). A checklist outlining the necessary risk assessment for HIV and HBV/HCV has been created which may be a useful tool in PEP consultations (see Appendix B).

### 9.2 | Initiating PEP

Routine blood test monitoring after initiation of INSTI-based PEP is not necessary unless clinically indicated or if baseline blood tests are abnormal.	2C
Take a contraceptive history and perform pregnancy testing in all women of childbearing age considering PEP and offer emergency contraception where indicated.	1D
Pregnancy and breastfeeding should not alter the decision to start PEP.	2D
Women must be counselled that antiretroviral agents used for PEP are unlicensed in pregnancy and their risks/benefits must be carefully discussed (see Section 10.2).	1D
An ultra-rapid course of HBV vaccination should be offered if clinically indicated in the absence of baseline immunity (see Figure 1, Section 9.4.2).	1B
Use of starter packs can negatively impact the completion of PEP, and therefore a full course of PEP should be provided at the first attendance unless there are operational reasons why this is not possible.	1C

Starter packs are pre-prepared with 5-day supplies of antiretrovirals which enables timely provision of PEP, especially out of hours or from emergency care facilities. This ‘starter’ PEP regimen can be continued or modified at initial review within 5 days, depending on further information about the index case’s HIV status, the index case’s viral load (and if viral load detectable, their resistance history) and the patient’s tolerance of the medication. If the index case tests negative in a fourth-generation laboratory assay, then PEP can be discontinued.

In a systematic review of the evidence on outcomes associated with starter packs for PEP compared to full prescriptions, PEP completion rates, stratified by prescribing practice, were pooled using random-effects meta-analysis. This included the following.

- Fifty-four studies providing data on 11714 PEP initiations.
- Thirty-seven studies, including three RCTs, providing information on starter packs (although none of the RCTs specifically assessed starter packs).
- Seventeen studies, including two RCTs, providing information on full prescriptions.

Overall, outcomes were nonsignificantly better when participants were offered a full 28-day PEP course at initial presentation to health care services than when they were offered starter packs, with fewer refusals [11.4% (95% CI 5.3–17.5%) vs 22% (95% CI 16.7–28.1%), respectively] and higher self-reported completion rates [70% (95% CI 56.7–77.3%) vs 53.2% (95% CI 44.4–62.2%), respectively] [137, 147]. More than a quarter (28%; 95% CI 21.4–34.5%) of individuals provided with a PEP starter pack failed to return for their subsequent appointment, and were therefore unable to receive the full course of PEP. The findings of this review suggested that starter packs do not improve acceptance and may negatively impact on PEP completion rates. The quality of the evidence overall, however, was rated as very low (and there may have been important differences in patient characteristics between studies that provided starter packs and those that provided full prescriptions), and therefore more research is needed [147].

In Britain, robust national-level data on PEP are lacking outside of sexual health services. However, recent audit data from two large centres in England have shown that around 80% of PEP initiated in emergency departments is prescribed for a high-risk indication, and therefore a full PEP course is required. Furthermore, around 10% of these patients with a high-risk exposure did not return to their planned follow-up appointment, and therefore discontinued PEP prematurely (unpublished data from University Hospital Sussex, UK). It may therefore be preferable for the majority of patients who require PEP to be given the full course at the first visit, removing the need for a second face-to-face attendance within 5 days to continue PEP. The use of less toxic drugs for PEP and a simplified approach to risk stratification by nonspecialists will facilitate this strategy of same-day full-course PEP provision. This approach may also be advantageous to services where access to follow-up appointments within 5 days is challenging (e.g. because of pandemic-related lockdowns). Based on the findings of the systematic review and audit data, we therefore recommend that a complete 28-day supply should be prescribed at the first attendance [148]. However, this change must be incorporated in PEP care pathways that ensure linkage to follow-up of baseline bloods tests, sexually transmitted infection (STI) testing, BBV follow-up, risk reduction interventions and transition to HIV PrEP where indicated.

If there are operational reasons why services need to use a starter pack, and stability data for raltegravir 600 mg in non-original packaging remain unavailable (Section 7.1.2), then raltegravir 400 mg twice daily is preferred as the third agent alongside TDF/FTC.

We encourage the conduct of local audits, in collaboration with BASHH/BHIVA, to better understand the national landscape of PEP use in accident and emergency departments, in SARCs, through private providers etc.

At presentation for PEP, and prior to administration of PEP, the following points (Box 2) must be discussed with the individual.

### 9.2.1 | Management of anxiety

Risk assessment and counselling are important to determine whether PEP is indicated and to manage individual concerns. The decision to administer PEP should be based on the risk of HIV acquisition and not to manage a state of acute anxiety following a potential HIV exposure. Calculating the likely HIV transmission risk relating to the incident (see **Section 5.5**) can be very reassuring to the attendee, who may frequently have overestimated the perceived risk. Referral for psychological support for individuals reporting anxiety related to the risk of HIV transmission may be beneficial.

### 9.3 | Baseline BBV testing of the index case

Following occupational exposures, informed consent for testing for blood-borne viruses [fourth-generation HIV test (HIV-1 Ag/Ab), HBV surface antigen (HBsAg) and HCV antibody (HCV Ab)] should be sought from the index case by another member of staff who is not the recipient of the occupational exposure.	GPP
If the index case is a child, then age-appropriate HIV, HBV and HCV testing should be used, depending on the age and developmental stage of the child, consent from the parent or legal guardian of the child, and consent or assent from the child. Discuss with a clinician with relevant expertise (e.g. a paediatric ID consultant or paediatric ID/microbiologist/virologist) if uncertain.	GPP
Where the index case is high risk for hepatitis C (e.g. PWID) then an HCV PCR or HCV antigen test can be done instead of an HCV Ab test.	GPP
Where it is not possible to seek consent from the index case (e.g. patient comatose or lacks mental capacity) then testing can be undertaken if it is in the best medical interests of the index case.	GPP

### Box 2 Items to discuss with individual commencing PEP

1. The rationale for PEP.
2. The lack of conclusive data for the efficacy of PEP.
3. The importance of starting PEP as soon as possible and of adherence to optimize efficacy.
4. The potential side effects of PEP.
5. Drug interactions, including those with over-the-counter drugs such as multivitamins/antacids/iron (iron should not be used with once-daily raltegravir, or, if an essential medication, iron should be spaced at least 4 h apart from twice-daily raltegravir dosing).
6. Emergency contraception (if appropriate).
7. The need to seek urgent medical attention if they develop symptoms of possible seroconversion.
8. The arrangement for early follow-up with either an occupational health or HIV/GU medicine clinic.
9. Verbal consent and HIV test (fourth-generation laboratory test).
10. The need to continue PEP for a minimum of 28 days if the baseline result is negative.
11. The need to have a follow-up HIV test a minimum of 45 days after completion of the PEP course – this is a minimum of 10.5 weeks post exposure if the 28-day course is completed.
12. The need to use condoms until the follow-up HIV testing is negative.
13. Coping strategies, assessment of vulnerabilities and social support.

Partner notification is recommended to test the index case for HIV as soon as possible; however, this must not delay PEP initiation. One European study found that following sexual intercourse with a source of unknown HIV status it was possible to contact and test the source in 43% of cases and subsequently avoid/discontinue PEPSE in 41%, benefits in terms of both cost saving and testing in a high-risk group [149, 150].

In order to undertake HIV testing for the purpose of determining the need to continue PEP, consent is required from the potential source. General Medical Council guidance should be followed for patients who lack capacity to consent (<https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/consent/part-3-capacity-issues#paragraph-75> accessed 24 April 2020). If a patient suspected of having a serious communicable disease lacks capacity to decide about testing, and is not likely to regain capacity soon, they can still

be tested if the team providing care determine it would be in their best interests to do so. In reaching that determination, the team should have regard to best practice guidance and clinical advice such as that published by the National Institute of Clinical Excellence (NICE), as well as what they know about the patient, their history, condition and wishes.

As long as the primary purpose of the test is in the patient's best interests, it would seem sensible to use the result to guide decisions for the secondary purpose of whether to provide PEP to a colleague who has incurred a needlestick injury. As the information was acquired for a legitimate purpose, it would not seem reasonable to expect the care team to ignore the result for the purpose of the risk assessment. In a recent case, the Supreme Court advised that, where there is evidence that a patient who currently lacks capacity would, had they had capacity, have been willing to agree to a medical procedure for the benefit of others, the doctor may be entitled to authorize the procedure in the patient's best interests (Aintree University Hospitals NHS Foundations Trust vs David James [2013] UKSC 67).

As HCV antibody positivity does not distinguish between past and current infections, where HCV antibody is positive reflex testing for HCV PCR should be performed. Where the index case has a risk factor for hepatitis C (e.g. PWID) then HCV PCR could be performed initially.

## 9.4 | Baseline and follow-up testing of recipient

Baseline and follow-up tests are summarized in Table 6.	1B
<b>All exposures:</b> blood testing before PEP initiation should include creatinine (and eGFR), alanine transaminase, HIV-1 Ag/Ab, HBV serology (if not known to be immune with HBsAb > 10 IU). PEP initiation should not be delayed by waiting for blood results.	
<b>Sexual exposure:</b> tests listed in 'All exposures' plus syphilis serology and HCV Ab in MSM and others at risk of hepatitis C.	
<b>Occupational exposure:</b> tests listed in 'All exposures' plus HCV Ab in all.	
Baseline pregnancy test in women of childbearing age considering PEP.	1D
Routine renal and liver function test monitoring after initiation of PEP is not necessary unless clinically indicated or if baseline blood tests are abnormal.	2C
Follow-up testing for HIV should be undertaken at a minimum of 45 days after completion of the PEP course. If the 28-day PEP course is completed, this is 73 days (10.5 weeks) post exposure.	1B
Follow-up testing for hepatitis B should be guided by hepatitis B vaccination status and baseline immunity as shown in Table 6 (Section 9.4.1) and Figure 1 (Section 9.4.2).	1B
For occupational exposures, after initiating PEP, we recommend individuals are followed up by their occupational health department as soon as possible, ideally within 72 h of the event.	1D

PrEP studies support the safety of tenofovir/FTC in HIV-negative individuals, and, despite small declines in

renal function with daily tenofovir (Table 6), these reversed on stopping tenofovir and the incidence of serious renal events was very low [117]. The RCT of raltegravir versus lopinavir/ritonavir PEP (combined with a Truvada backbone) did not report any liver, renal or haematological abnormalities in the raltegravir arm [131]. INSTIs are less commonly associated with transaminitis and hepatic adverse events than PIs [151]. The most at-risk group for liver dysfunction are those coinfecting with HCV [152]. Closer monitoring is, however, recommended if new symptoms develop on PEPSE (e.g. rash, jaundice or muscle pain), if the recipient is pregnant, if there is a risk of drug–drug interaction, if significant comorbidities such as hepatitis or renal dysfunction exist or if significant

abnormalities are detected on baseline testing. Creatinine kinase (CK) should be tested if muscle pain develops on PEP, particularly on INSTI-based PEP.

Several national audits report that the attendance for follow-up HIV testing at 12 weeks is poor (30–67%) [38–44] so we suggest services use local mechanisms, including text/email reminders, to encourage attendance for post-exposure HIV testing. The HIV test must be in a fourth-generation laboratory assay.

Hepatitis B vaccination is routinely recommended for HCWs, laboratory staff, staff of residential accommodation, emergency service workers, PWID, MSM, sex workers and close contacts of individuals with chronic HBV infection, as well as in other scenarios outlined in the Green Book

TABLE 6 Baseline and follow-up testing

	Baseline	2 weeks	12 weeks	6 months
<b>SEXUAL EXPOSURES ONLY</b>				
STI testing (per local policy)	✓	✓	✓Syphilis only (and other STIs If further unprotected sexual intercourse)	
<b>ALL EXPOSURES</b>				
Creatinine and eGFR	✓	Only if abnormalities at baseline		
Alanine transaminase	✓	Only if abnormalities at baseline or symptomatic		
Pregnancy test	✓	If appropriate	If appropriate	
HIV	<b>HIV-1 and HIV-2 Ag/Ab</b>		<b>HIV-1 and HIV-2 Ag/Ab<sup>a</sup></b>	<b>Not required unless further exposures</b>
Hepatitis B	<b>HBsAb, HBsAg, HBeAb</b> <i>For immunocompetent adults who have completed HBV vaccination and responded (HBsAb ≥10 IU at any time), no baseline or follow-up HBV testing is required</i>		<i>If unvaccinated or HBsAb &lt;10 IU at the time of exposure:</i> <b>HBsAb, HBsAg</b>	<i>Only advised if HBsAb remains &lt;10 IU at 12 weeks:</i> <b>HBsAg</b>
Hepatitis C	<b>HCV Ab</b>		<b>HCV Ab</b> <i>If high risk exposure e.g. HCV+ index, then HCV PCR or HCV Ag is preferable as the window period is shorter for antigen-based tests and can be requested as early as 2 weeks post exposure</i>	<i>If high risk exposure, e.g. HCV+ index case and testing at week 12 negative:</i> <b>HCV Ab</b>

Ab, antibody; Ag, antigen; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; HBsAb, HBV surface antibody; HBsAg, HBV surface antigen; HCV, hepatitis C virus; PCR, polymerase chain reaction; STI, sexually transmitted infection.

<sup>a</sup>HIV testing can be done a minimum 45 days after completion of the post-exposure prophylaxis (PEP) course (see British HIV Association HIV testing guidelines for further information). If the 28-day PEP course is completed, this is 73 days (~10.5 weeks) post exposure. For sexual exposure, to align with syphilis follow-up testing at week 12, the HIV test can be done at the same visit.

([https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/628602/Green\\_book\\_chapter\\_\\_18.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/628602/Green_book_chapter__18.pdf)). Some employees presenting for PEP will be unaware of their HBsAb titre, so it is therefore advisable to present to occupational health (OH) departments during working hours as the OH department should be privy to this information. Regardless of the type of exposure, if there is documentation of HBsAb titre of > 10 IU, this person is deemed a responder to vaccination with adequate immunity against hepatitis B and no further follow-up testing is required [153]. A significant proportion of individuals present to emergency departments or sexual health services following occupation or sexual exposures; for those in whom vaccination status is unclear or who do not have documented immunity to hepatitis, we suggest offering a booster/first dose of hepatitis B vaccine while results of HBsAb are awaited. If the individual is unvaccinated or HBsAb < 10 IU at the time of exposure and the exposure is deemed higher risk, an ultra-rapid course of hepatitis B vaccination should be continued [or HBV immunoglobulin (HBIG) if the index case is known to be HBsAg positive] as per BASHH guidelines and the Green Book, Chapter 18 [154].

Occupational health services have the responsibility for vaccinations and follow-up blood testing for occupational exposures.

HCV is only extremely rarely transmissible through penile–vaginal intercourse or oral sex, so baseline and follow-up hepatitis C testing is only indicated in MSM who have had condomless anal sex (further details in BASHH guidelines), PWID and occupational exposures. Where there has been a significant risk (e.g. needlestick from HCV-positive index case), HCV core antigen or HCV RNA tests should be considered as these tests have a shorter window period and can be considered as early as 2 weeks post exposure [155]. Final testing for hepatitis C can be done at 12 weeks with HCV core antigen or HCV RNA, or at 6 months with an HCV antibody test. Refer on to hepatology services where an HCV infection is identified.

#### 9.4.1 | Sexual health considerations

Perform chlamydia, gonorrhoea and syphilis testing (based on clinical situation) at baseline and repeat testing following the incubation period.	2C
Emergency contraception should be offered where indicated.	1B
Offer MSM hepatitis A and human papilloma virus vaccines (in addition to HBV vaccine) if clinically indicated as per the 2016 BASHH MSM guidance.	1B
Individuals presenting for PEP who may be at higher risk of future acquisition of HIV should be encouraged to attend for regular sexual health checks and considered for referral to risk-reduction services including HIV PrEP.	2C

Provision of PEP should be fully integrated into counselling around safer sex strategies, including the opportunity to meet with an appropriate health care professional competent in sexual health advising. 1C

Observational studies have found that 15–17% of PEP recipients had an STI at baseline and an additional 4–5% had an STI diagnosed at 2 weeks post exposure [156, 157]. As loss to follow-up is common in PEPSE recipients, we recommend opportunistic STI testing at baseline, unless the patient presents for PEPSE following sexual assault, where, if still within the time frame where forensic samples may be obtained (usually within 7 days of assault), STI screening should be deferred until after forensic samples have been taken. We suggest offering MSM presenting for PEP hepatitis A and human papilloma virus vaccines opportunistically as per the 2016 BASHH MSM guideline [101].

##### 4.1.1 | Risk reduction interventions

Provision of PEPSE should be fully integrated with advice and counselling around safer sex strategies. Early assessment in a specialist sexual health service, including meeting with a counsellor/sexual health advisor, has been shown to improve rates of adherence and follow-up HIV testing [158, 159]. Individuals presenting for PEPSE are at higher risk of future acquisition of HIV [160] and so should be encouraged to attend for future regular sexual health check-ups and considered for referral to risk-reduction services including HIV PrEP. We recommended that all MSM and other high-risk groups have documented discussions around PrEP use as per the BASHH PrEP guideline (see Section 11) [161].

#### 9.4.2 | Occupational health considerations

Whilst it may be necessary for individuals to present to emergency care departments out of hours, we recommend that they are seen by their occupational health department within 3 days of the event. Occupational health services have the responsibility for urgent testing of the index case (in conjunction with the index case's attending medical team), hepatitis B vaccinations if required, advice to the PEP user during the course and the follow-up blood testing. The Health and Safety Executive website provides information on actions following occupational exposures and how to report them (<http://www.hse.gov.uk/healthservices/needlesticks/actions.htm>). Occupational exposures where the index case has a BBV should also be reported to Public Health England via the SigOcc system (<https://www.gov.uk/government/collections/blood>



borne-viruses-bbvs-in-healthcare-workers). Public Health England have produced guidance on management of exposure to BBV for emergency care workers and can provide guidance for HCWs undertaking exposure-prone procedures following occupational exposure, or for health clearance in the case of subsequent exposure (<https://www.gov.uk/government/groups/uk-advisory-panel-for-healthcare-workers-infected-with-bloodborne-viruses>) [82]. Institutional policies on managing blood and body fluid exposures should be available to staff. The policy that covers the relevant legislation (e.g. Control of Substance Hazardous to Health) should also be readily available to the employees.

The stress experienced by some individuals is extreme. In most cases, counselling on the actual risk of the exposure is an effective tool in managing the employee's anxiety. In addition, the benefits and disadvantages of PEP should be discussed with the employee.

## 10 | SPECIAL SCENARIOS

### 10.1 | Chronic HBV infection

Baseline HBV testing should be undertaken in those of unknown HBV status, and vaccination (and HBIG, depending on risk of exposure) initiated in those who are not known to be immune whilst awaiting results.	GPP
Consider the use of a standard PEP regimen for individuals known to have chronic HBV and on either an NRTI [except if on combined therapy with tenofovir (TDF)/lamivudine or TDF/FTC] or pegylated IFN-alpha-based HBV treatment, where high-risk HIV exposure has occurred.	1B
Individuals found to have HBV infection at baseline should receive PEP as needed without delay.	1B
Individuals found to be HBV-infected at baseline should be assessed by a specialist in HBV infection with regard to continuing HBV therapy post-PEP. If the assessment does not fall within the 28-day PEP course, then tenofovir/FTC should be continued pending the assessment.	1B

Chronic HBV infection remains the most prevalent of the BBV infections globally. Current HBV management guidelines recommend treatment of chronic HBV infection based on age, HBV DNA levels and stage of fibrosis, and for individuals at risk of hepatocellular carcinoma. Therapy is either of finite duration with pegylated IFN-alpha (milder disease) or of finite or indefinite duration with HBV-active NRTIs. NRTIs with a high barrier to resistance, tenofovir (TDF or TAF) and entecavir as single therapy are recommended when

NRTIs are chosen as the treatment option. Lamivudine is no longer recommended as single-agent therapy for chronic HBV infection because of its low genetic barrier to resistance. Both tenofovir (TDF and TAF) and lamivudine (and FTC) have dual activity against HBV and HIV.

Current data and guidelines recommend TDF and FTC/lamivudine as effective PrEP against HIV infection, and TDF as monotherapy, when FTC is contraindicated for PrEP in heterosexual men and women for prevention of sexual transmission of HIV [25, 116, 161, 162].

On-treatment hepatic flares have been noted in patients on NRTI-based therapy. Concerns have also been raised about NRTI-withdrawal hepatic flares, and their clinical consequences. However, the iPrEx study demonstrated that it was possible to use TDF/FTC in patients with chronic HBV infection and, importantly, demonstrated the ability to stop TDF/FTC safely in patients without cirrhosis and without the occurrence of significant hepatic flares, although this needs specialist input [163].

Whilst the use of dual-acting NRTIs has high efficacy in preventing HIV infection, either as PrEP (TDF alone or in combination with FTC or lamivudine) or as PEP (TDF with FTC or lamivudine or lamivudine-containing combination therapy), questions remain around:

- the need for HIV PEP in patients with chronic HBV infection, established on continuous therapy with tenofovir for the treatment of their chronic HBV infection;
- the safety of short-duration tenofovir and FTC/lamivudine-based PEP for patients with chronic HBV not on HBV treatment.

Our recommendation around HBV screening, vaccination and, where necessary, HBIG is in accordance with the BASHH hepatitis guideline (<https://www.bashhguidelines.org/media/1161/viral-hepatitides-2017-update-18-12-17.pdf>). Pegylated IFN-alpha, lamivudine, telbivudine and entecavir do not provide prophylaxis against HIV. TDF monotherapy has pre-exposure prophylactic efficacy against HIV in heterosexual men and women following sexual exposure. TDF monotherapy has not yet been reported in MSM, although it is likely to be effective in PrEP as TDF concentrates in rectal tissue. However, breakthrough infections have been described, probably associated with inadequate drug levels, and therefore standard multi-drug PEP could be considered [164, 165]. On-treatment hepatic flares are relatively rare in patients with chronic HBV infection on NRTI-based therapy, and when they do occur do not lead to hepatic decompensation events in noncirrhotic patients and may well be associated with HBsAg clearance [163]. Treatment-withdrawal flares are also relatively rare, and self-limiting in patients with minimal/mild fibrosis not in need of HBV therapy [163, 166-168]. The risk of

tenofovir or lamivudine (or FTC) HBV resistance with 4 weeks of therapy is also extremely low.

## 10.2 | Pregnant and breastfeeding mothers

Take a contraceptive history and request a baseline pregnancy test in women of childbearing age considering PEP.	1D
Pregnancy and breastfeeding should not alter the decision to start PEP.	2D
For women who are pregnant, raltegravir 400 mg twice daily is preferred as the third agent. Where accessing raltegravir 400 mg might cause delay, we recommend using raltegravir 600 mg twice daily and switching at the earliest opportunity.	1C
For women at risk of pregnancy or known to be within the first 6 weeks of pregnancy who cannot use first-line for PEP for any reason, we recommend avoiding the use of dolutegravir as an alternative third agent (Table 5, Section 7.1.3).	1C
For women beyond 6 weeks of pregnancy, dolutegravir can be used as an alternative third agent.	1C
Women should be counselled that antiretrovirals used for PEP are unlicensed in pregnancy and that their risks/benefits must be carefully discussed (see Section 10.2).	1D
Women who are breastfeeding must be counselled regarding the transfer of antiretrovirals to the infant via the breastmilk.	1D

Pregnancy is not a contraindication for PEP. Pregnant women are at increased risk of HIV transmission and the high viraemia associated with primary infection would lead to a high likelihood of intrauterine infection [78]. We suggest that a thorough risk assessment should be undertaken in all women of childbearing age considering PEP, including a contraceptive history and pregnancy testing. It is important to explain that a negative urine pregnancy test at baseline is too early to exclude pregnancy as most urine pregnancy tests take 3 weeks from conception to become positive.

The Antiretroviral Pregnancy Registry (APR) (<http://www.apregistry.com>) is a surveillance study of pregnancy outcomes in women exposed to antiretrovirals during pregnancy in North America and Europe. At the time of writing, the APR includes data from 1 January 1989 to 31 July 2019. Combined with animal toxicology studies and studies undertaken in pregnant women (e.g. pharmacokinetics), the APR can assist clinicians and patients in making treatment decisions. The SPCs in relation to pregnancy for the antiretroviral agents used in PEP are summarized in Appendix D.

For darunavir, raltegravir and elvitegravir, there are sufficient data to be able to detect at least a 2-fold increase in risk of overall birth defects, and no such increases have

been detected to date (APR accessed 09/01/2020). For tenofovir and FTC, there are sufficient data to detect at least a 1.5-fold increase in the risk of overall birth defects and a 2-fold increase in the risk of birth defects in the more common classes, cardiovascular and genitourinary systems; no such increases have been detected to date [141].

For dolutegravir, although an initial meta-analysis suggested that it appeared safe to use in pregnancy, in 2018, a preliminary unscheduled analysis of an ongoing birth surveillance study in Botswana reported an increased risk of NTDs [169]. In 2019, further data for 1683 women in the Tsepamo study, a prospective surveillance study in Botswana, reported five NTDs (prevalence 0.3%) in women conceiving on dolutegravir [170]. As presented at the 2020 IAS conference, the latest analysis found that the apparently elevated risk of NTDs with dolutegravir has diminished further; prevalence of NTDs among women conceiving on dolutegravir has decreased to 0.19% (seven NTDs in 3591 deliveries), compared to 0.11% for other antiretrovirals, and the difference is no longer statistically significant [171].

In the latest data from the APR, there was only one NTD reported among 248 women exposed to dolutegravir during conception, leading to a prevalence of 0.4%, only slightly higher than with other antivirals [172]. However, this estimate is based on a single NTD among a relatively small number of exposures. Having reviewed the available data, the guideline working group suggests that, for women at risk of pregnancy or known to be within the first 6 weeks of pregnancy, the use of dolutegravir should be avoided where other suitable options exist pending further safety data.

The prescribing advice in pregnancy for antiretrovirals included in this policy, at the time of writing, is summarized in Appendix D, but prescribers should ensure that they check the most recent version of the Summaries of Product Characteristics and the BHIVA pregnancy guideline when prescribing PEP to pregnant women. It is important to note that antiretrovirals used for PEP are unlicensed in pregnancy, and therefore the writing group recommends that women should be counselled appropriately, including discussion of the risks and benefits. Women of childbearing age who are not pregnant at the start of PEP should be given accurate information regarding the full range of contraceptive choices available. Expert opinion from the guideline working group is that, with the exception of dolutegravir in the first 6 weeks of pregnancy and elvitegravir in the second and third trimesters, any of the antiretrovirals can be used as PEP in pregnancy because the benefits outweigh the risks.

### 10.2.1 | Breastfeeding

Breastfeeding is also not a contraindication for PEP as the benefits outweigh the risks to both the woman and the

infant. Although nearly all data relating to antiretroviral drug exposure in breastfed infants are from low- and middle-income countries, the guideline writing group recommend that women who are breastfeeding should be counselled appropriately.

ART taken by the mother can enter breastmilk through active transport mechanisms and by passive diffusion and therefore be ingested by the breastfeeding infant [173]. However, it is difficult to quantify precisely how much drug the breastfed infant is exposed to because the overall drug accumulation in breastmilk and the subsequent exposure to the breastfed infant are dependent on a number of maternal (e.g. maternal antiretroviral dosing, drug pharmacokinetics and stage of lactation) and infant (e.g. suckling pattern, i.e. volume of milk consumed, frequency and timing relating to maternal concentrations) factors. It is thought that drugs with lower maternal dosing, a shorter half-life or higher protein binding are less likely to accumulate in breastmilk. The stage of lactation determines the protein and fat content in breastmilk, which changes with the transition from colostrum to mature milk shortly after birth [174].

Although data are not available for all antiretroviral drugs, a meta-analysis conducted in 2015 of pharmacokinetic studies found that infants that are exclusively breastfed receive up to 10% of the weight-adjusted infant dose of NRTIs and NNRTIs [175]. Data from a case report and an RCT have demonstrated that transfer of dolutegravir to the infant occurs via breastmilk [176, 177]. In the DolPHIN-1 study, where HIV positive, treatment-naïve pregnant women in Uganda and South Africa were randomized to initiate either dolutegravir- or efavirenz-containing ART in the third trimester and until 2 weeks post-partum, breastfeeding led to significant plasma exposures in the infant, despite low plasma dolutegravir concentrations [176]. It is also thought that there is delayed clearance of dolutegravir by the infant as a consequence of an immature UDP-glucuronosyltransferase (UGT1A1) gene polymorphism, which can lead to prolonged exposure to dolutegravir in breastfed infants [178]. There are no breastmilk pharmacokinetic data for other antiretrovirals recommended for PEP, including TAF.

### 10.3 | Use of PEP in populations using PrEP

The need for PEP (i.e. a significant potential risk within the last 72 h) should be considered in all individuals requesting PrEP, prior to transitioning to PrEP. 1B

Decisions about the need for PEP in the setting of people on PrEP but with less than optimal PrEP adherence depends on the length of time since the last dose of PrEP and the site of exposure. 1C

Anal sex: if the only exposure has been through anal sex and for people on daily PrEP, where fewer than four pills have been taken in the last 7 days then the need for PEP should be risk assessed. For people on event-based PrEP, PEP is indicated where PrEP has not been taken as recommended. 1A

Vaginal: where the potential HIV exposure is through vaginal sex and PrEP adherence has been suboptimal, PEP should be considered if > 48 h has elapsed since last dosing or if fewer than six tablets have been taken within the previous 7 days. 1B

Frontal or neovaginal sex: where the potential exposure to HIV is through frontal sex in trans men or through neovaginal sex in trans women, then PEP should be considered if more than 48 h has elapsed since last dosing or if fewer than six tablets have been taken within the previous 7 days. 1C

People using PrEP are at high risk of HIV acquisition and therefore, in the context of recent potential exposure to HIV, may be eligible for PEP as a result of imperfect PrEP adherence, which places them at risk of incident HIV infection [179]. Data from pharmacokinetic studies and PrEP clinical trials provide good evidence for the minimal adherence required for PrEP efficacy for anal sex [180, 181] and for vaginal sex [182, 183]; there are fewer data for frontal sex in trans men on androgen therapy or for neovaginal sex in trans women, but principles for levels of adherence to maintain protective tissue concentrations in peripheral blood mononuclear cells (PBMCs) can be extrapolated [183]. In general, time to protection for TD is shortest in lower gastrointestinal tract tissues, followed by blood PBMCs and then the female genital tract tissues. Therefore, adherence levels required for protection against HIV acquisition from anal sex are lower than those required for vaginal, trans vaginal or frontal sex, because of the persistence of tenofovir/FTC in rectal tissues. Therefore, recommendations for PEP differ by site of exposure in terms of time since last dose and pattern of adherence prior to exposure.

### 10.4 | When to discontinue PEP because of missed doses

Individuals missing doses of PEP should be counselled according to the number of missed doses and the time elapsed from the last administered dose. Persistence of PEP medications at therapeutic levels will depend on the pharmacokinetic properties of the individual agents used.

Pharmacokinetic studies have shown that the half-life of raltegravir 1200 mg once daily is approximately 8–12 h [184]. The tenofovir/FTC plasma half-lives are 12–18 h according to the SPC [185] but were longer in a recent study: 31 and 37 h for tenofovir and FTC,

respectively [186]. Tenofovir and FTC are activated intracellularly and the median intracellular half-lives are approximately 150–160 h [186, 187] and 39 h [186], respectively. Recommendations on whether and when to discontinue PEP after missed doses are largely empirical, based on biological and pharmacological rationales as well as expert opinion:

*What if I miss my dose?*

- If you forget to take a dose, take it as soon as you remember it.
- However, if it is time for your next dose, skip the missed dose and go back to your regular schedule.
- Do not take a double dose to make up for a forgotten dose.
- If more than 48 h has elapsed since the last dose, then discontinue PEP.

If interruption of PEP (for less than 48 h since the last missed dose) is related to intolerance to one or more ART agents, continue PEP with an alternative agent(s) (see Table 4, **Section 6.5**). For dolutegravir-based PEP, if > 72 h has elapsed since the last dose, then PEP should be discontinued.

## 10.5 | Seroconversion during PEP

Individuals experiencing a skin rash or flu-like illness while or after taking PEP should be advised to attend for urgent review to exclude an HIV seroconversion.	2D
--	----

If the HIV test is positive after PEP has already been initiated, PEP should be continued pending review by an HIV specialist.	GPP
--	-----

HIV testing is mandatory prior to, or shortly after, commencing PEP (1A) as undiagnosed HIV infection would significantly alter the risk–benefit balance of short-course ART. Service providers may obtain rapid results through point-of-care tests (POCTs), although caution must be exercised given the higher possibility of both false-positive results and, in early infection, greater likelihood of missing very early HIV infection. If a POCT is reactive, a fourth-generation serological test should be sent urgently, and expert advice sought prior to initiating PEP.

If the fourth-generation HIV test is positive after PEP has already been initiated, we recommend continuing PEP pending review by an HIV specialist. Acute HIV diagnosis after PEPSE initiation represents a unique opportunity for very early ART and the potential benefits that entails [188]. Furthermore, stopping ART in the context of acute infection may result in significant viral rebound which could increase the risk of onward transmission [189].

## 10.6 | Further high-risk exposures while on PEP

In the event of a further high-risk sexual exposure during the last 2 days of the PEP course, PEP should be continued until 48 h after the last high-risk exposure for anal sex or until 7 days after the last high-risk exposure for vaginal/frontal sex.	2B
--	----

TD/FTC has been shown to prevent acquisition of HIV infection when used as PrEP by MSM [118, 119]. Individuals reporting further high-risk sexual exposures while receiving PEP do not need to extend the course of PEP beyond the initial 28 days. However, should this exposure be during the last 2 days of the course, then extending the treatment for 48 h after the last exposure should be advised for MSM, as this appears to have been highly effective in the IPERGAY study of intermittent PrEP (2B) [119]. In the vagina/neovagina, however, tenofovir levels decline rapidly after discontinuation, so in the event of a repeated high-risk exposure then PEP should be continued for 7 days after the last high-risk exposure [161].

## 11 | RECOMMENDATIONS FOR PREP IN THOSE WITH ONGOING HIGH-RISK BEHAVIOUR

Repeat attenders should meet with a sexual health adviser and/or psychologist, and provision of PEP should be fully integrated into counselling around safer sex strategies.	1C
--	----

PEP should not be considered or encouraged as a first-line method of HIV prevention.	1C
--	----

Individuals presenting for PEP who are likely to have ongoing high-risk behaviour should be transitioned immediately to PrEP. HIV testing with a combined antigen/antibody laboratory-based test should be performed at the time of transition.	GPP
---	-----

In a study on the outcomes in MSM given PEP following sexual exposures at sexual health clinics across England, between 2011 and 2014, PEP was prescribed for 24 004 total episodes, of which 16 422 (68%) were in MSM. Compared with MSM attendees not prescribed PEP, MSM prescribed PEP were significantly more likely to subsequently acquire HIV [for a single PEP course: adjusted HR (aHR) 2.54; 95% CI 2.19–2.96; for two or more PEP courses: aHR 4.80; 95% CI 3.69–6.25]. In the PROUD study, some particularly high-risk subpopulations had high repeat PEP usage and, despite this, a high incidence of HIV acquisition (probably attributable to

ongoing risk behaviour which may or may not be covered by PEP).

Repeated attenders should be considered for repeat courses of PEP on each occasion according to their risk of HIV acquisition. Provision of PEP should be fully integrated with advice and counselling around safer sex strategies (1C). It is recommended that, in light of the NICE (2007) recommendations (<https://www.nice.org.uk/guidance/ph3>), these repeat attenders are offered one-to-one structured discussions around a model of behaviour change theory which can address factors that can help reduce risk-taking and improve self-efficacy and motivation.

The writing committee believes that it is crucial to consider PEP as only one strategy for preventing HIV infection and it must be considered within the broader context of HIV prevention. Other methods of HIV prevention have a more robust evidence base and so PEP should not be considered as a first-line method of HIV prevention (1C). Condoms are highly protective, although use is inconsistent [54, 190]. Data in support of treatment of HIV positive partners as a prevention strategy are strong [55, 56].

PrEP is an evidence-based and highly effective method of HIV prevention (<https://www.bhiva.org/PrEP-guide-lines>) [191]. Attending for PEP is an ideal opportunity to offer individuals PrEP [192]. Individuals who are likely to have ongoing high-risk behaviour should be transitioned immediately from PEP to PrEP. HIV testing with a combined antigen/antibody laboratory-based test should be performed at the time of transition.

## 12 | AWARENESS OF PEP

It is important that individuals at risk of acquiring HIV are aware of PEP. Whether or not an individual seeks PEP may be related to whether the episode was 'unusual' or a 'one off' and influenced by factors such as characteristics of the sexual partner(s), the venue and the use of alcohol and/or recreational drugs [193]. Community-based organisations will have a large part to play in providing this information. Consideration should be given to provision of 24-h helpline access to enable individuals to establish whether presentation to hospital services for PEPSE is appropriate (2D). Sexual assault referral centres should ensure that clients and police officers are aware of PEP, and the need for a risk assessment of HIV transmission in each case.

PEP should be proactively discussed with individuals diagnosed with HIV infection, particularly if in a serodifferent relationship, or reporting frequent partner change or condomless sexual intercourse (GPP).

## 13 | COST-EFFECTIVENESS

The medication cost of a full 28-day course of PEP (with generic tenofovir/FTC and raltegravir) is approximately £549 (British National Formulary list price January 2021), and the lifetime cost of treatment for an HIV positive individual is estimated to be approximately £360 000 [194]. A 2009 systematic review of PEPSE included four economic evaluations. The methodological quality of the studies was variable, but results suggest that PEP following nonoccupational exposure to HIV was cost-saving for men who have condomless receptive anal sex with men, whether the index partner is known to be HIV positive or not; heterosexuals after condomless receptive anal intercourse; and injecting drug users sharing needles with a known HIV positive person. PEP following nonoccupational exposure to HIV was cost-effective for all male-male intercourse (condomless receptive and insertive anal sex, condomless receptive oral sex, and 'other') and was possibly cost-effective for injecting drug users and women at high risk [22]. This is in general accordance with a review by the Health Technology Assessment [22]. The more recent recognition that an undetectable HIV viral load is effective in preventing onwards transmission may impact future cost-effectiveness analyses. A 28-day course of PEP could be substantially less expensive with the use of generic medications available now or in the future.

## 14 | SURVEILLANCE OF THE USE OF PEP

### 14.1 | Sexual exposures

Since January 2011, all episodes of PEP dispensed from genitourinary medicine (GUM) clinics in England have been reported through the GUMCAD system (<https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables>). Reported PEPSE use amongst MSM had risen annually, but appears to have declined in 2018 since PrEP has been more available (Table 7).

### 14.2 | Occupational exposures

There are no routine national data collected on the total number of occupational exposures or courses of PEP given following occupational exposures. Since 1997, PHE has collected data on significant occupational exposures (SOEs) where the index case is either known or thought to be living with HIV, hepatitis B and/or hepatitis C, the findings of

TABLE 7 Reported use of PEPSE via GUMCAD 2014–2018

	2014	2015	2016	2017	2018
Male heterosexual	1120	1382	1468	1537	1637
MSM	5904	8031	9083	9849	8413
Female heterosexual	1156	1285	1337	1631	1678
Women who have sex with women	26	47	57	38	50
Total	8415	10,995	12,146	13,427	12,372

which are summarised the Eye of the Needle Report [17]. Many occupational exposures are seen in accident and emergency departments and followed up in sexual health clinics so may contribute to the above GUMCAD figures.

## 15 | QUALIFYING STATEMENT

The recommendations in this guideline may not be appropriate for use in all clinical situations. Decisions to follow these recommendations must be based on the professional judgment of the clinician and consideration of individual patient circumstances and wishes. It should be acknowledged that use of any antiretroviral agent in this setting is an unlicensed indication. All possible care has been undertaken to ensure the publication of the correct dosage and route of administration. However, it remains the responsibility of the prescribing physician to ensure the accuracy and appropriateness of the medication they prescribe.

## 16 | APPLICABILITY

The provision of PEPSE requires consideration of appropriate pathways of care between sexual health/HIV clinicians and those providing emergency/primary care, including SARCs, in order to ensure PEPSE is administered in a timely and appropriate fashion. This will require local interpretation of this guideline and will probably involve a degree of organizational change and provision of additional resources.

These guidelines and the relevant literature will be reviewed at 5 years after publication as per the BASHH framework for guideline production. If any significant data are published in the interim, there will be an interim guideline statement issued.

## 17 | AUDITABLE OUTCOME MEASURES

We recognize that audit may be challenging where different services are providing the initial PEP prescription and

follow-up. Services should therefore decide which outcome measures are more applicable to their setting. We suggest that occupational health services undertake annual notes review of occupational PEP to ensure practice consistent with nonoccupational standards.

1. Proportion of PEP attendees having a baseline HIV test performed: aim 100% within 1 working day of presenting for PEP.
2. Proportion of PEP attendees having a HIV test result available within 5 days: aim 97%.
3. Proportion of PEP prescriptions that fit within recommended indications (consider or recommended): aim 90%.
4. Proportion of PEP prescriptions administered within 24 h of risk exposure: aim 70%.
5. Proportion of individuals completing 4-week course of PEP: aim 75%.
6. Proportion of individuals prescribed PEP undergoing testing for STIs: aim 90%.
7. Proportion of individuals for whom completion of 4-week course of PEP is indicated who undergo HIV antibody/antigen test at least 45 days after the completion of PEP: aim 75%.
8. Proportion of patients presenting for nonoccupational PEP who have a documented discussion about PrEP if eligible: aim 90%.

## ACKNOWLEDGEMENTS

The writing group thanks the following for their valuable contribution to the guideline: Simon Collins (i-base), Catriona Waitt (University of Liverpool), Emily Phipps (PHE), Ellen Heinsbroek (PHE), Steve Taylor (PHE) and the Library team at Brighton and Sussex University Hospital.

## CONFLICTS OF INTEREST

LW has received speaker/advisory fees from Gilead, ViiV, MSD, Janssen, Cipla, Mylan, Theratech and been involved in pharmaceutical-sponsored clinical trials by Gilead, Janssen. FVC was funded by Wellcome (210772/Z/18/Z)

and is involved in a Janssen-funded clinical trial. NG received speaker fees from Gilead. SB has received speaker fees for Educational Programmes, fees for attending advisory boards, and research funding from Gilead, MSD, GSK, Roche and Sob.

## ORCID

Fiona Cresswell  <https://orcid.org/0000-0002-5070-532X>

Valerie Delpach  <https://orcid.org/0000-0002-9952-8109>

Jayne Ellis  <https://orcid.org/0000-0002-7009-9144>

Paul Rafferty  <https://orcid.org/0000-0001-9279-7501>

Laura Waters  <https://orcid.org/0000-0002-1379-1775>

Alison Rodger  <https://orcid.org/0000-0001-8817-4651>

Nadi Gupta  <https://orcid.org/0000-0002-4519-9274>

## REFERENCES

- Expert Advisory Group on AIDS. Change to recommended regimen for post-exposure prophylaxis (PEP), 2015. Available from: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/351633/Change\\_to\\_recommended\\_regimen\\_for\\_PEP\\_starter\\_pack\\_final.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/351633/Change_to_recommended_regimen_for_PEP_starter_pack_final.pdf)
- British Association for Sexual Health and HIV CEG. Framework for Guideline Development and Assessment, 2014. Available from: <http://www.bashh.org/documents/GUIDELINES%20FRAMEWORK%20April%202015.pdf>
- Benn P, Fisher M, Kulasegaram R, Bashh, Group PGWGCE. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). *Int J STD AIDS*. 2011; 22(12): 695–708.
- Centre for Disease Control. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States Morbidity and Mortality Weekly Reports, 2005/54(RR02);1-202005. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm>
- World Health Organisation. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children. 2014.
- Australian Society for HIV Medicine. National guidelines for post-exposure prophylaxis after non-occupational and occupational exposure to HIV 2013. Available from: <http://www.ashm.org.au/Documents/Guide-for-the-Management-of-Occupational-and-Non-Occupational-Post-Exposure-Prophylaxis.pdf>
- Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. *Am J Med*. 1997; 102 (5B): 21–24.
- Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. *J Exp Med*. 1996; 183(1): 215–225.
- Hope T, Visualizing HIV. Visualizing HIV Transmission and Prevention. Conference on Retroviruses and Opportunistic Infections Madrid, 2018.
- Bourry O, Mannioui A, Sellier P, et al. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. *Retrovirology*. 2010; 7: 78.
- Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. *J Virol*. 1998; 72(5): 4265–4273.
- Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). *J Virol*. 2000; 74(20): 9771–9775.
- Grand RL, Vaslin B, Larchero J, et al. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. *AIDS*. 2000; 14(12): 1864–1866.
- Bourry O, Brochard P, Souquiere S, et al. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and didanosine. *AIDS*. 2009; 23(4): 447–454.
- Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, Heptonstall J, Ippolito G, Lot F, McKibben PS, Bell DM. A Case-control study of HIV seroconversion in health care workers after percutaneous exposure. *N Engl J Med*. 1997; 337(21): 1485–1490.
- Hawkins DA, Asboe D, Barlow K, Evans B. Seroconversion to HIV-1 following a needlestick injury despite combination post-exposure prophylaxis. *J Infect*. 2001; 43(1): 12–15.
- Public Health England. Eye of the Needle Report. Surveillance of significant occupational exposures to bloodborne viruses in healthcare workers in the United Kingdom – update on seroconversions, 2020.
- Woode Owusu M, Wellington E, Rice B, Gill ON, FN. *Eye of the Needle: United Kingdom Surveillance of Significant Occupational Exposures to bloodborne Viruses in Healthcare Workers*. Public Health England, 2014.
- Tomkins S, Ncube F. Occupationally acquired HIV: international reports to December 2002. *Weekly Releases*. 2005; 10(10): E050310 2
- Evans BG, Abiteboul D. A summary of occupationally acquired HIV infections described in published reports to December 1997. *Eurosurveillance*. 1999; 4(3): 29–32.
- Li H, Blair L, Chen Y, et al. Molecular mechanisms of HIV type 1 prophylaxis failure revealed by single-genome sequencing. *J Infect Dis*. 2013; 208(10): 1598–1603.
- Bryant J, Baxter L, Hird S. Non-occupational postexposure prophylaxis for HIV: a systematic review. *Health Technol Assessment*. 2009; 13(14): iii, ix-x, 1–60.
- Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. *J Acquir Immune Deficiency Syndrom*. 2004; 35 (5): 519–525.
- Donnell D, Mimiaga MJ, Mayer K, Chesney M, Koblin B, Coates T. Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. *AIDS Behav*. 2010; 14(5): 1182–1189.
- Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2013; 381(9883): 2083–2090.

26. Beymer MR, Kofron RM, Tseng C-H, et al. Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. *Int J STD AIDS*. 2018; 29 (6): 557–562.
27. Foster R, McAllister J, Read TR, et al. Single-tablet emtricitabine- rilpivirine-tenofovir as HIV postexposure prophylaxis in men who have sex with men. *Clin Infect Dis*. 2015; 61(8): 1336–1341.
28. Inciarte A, Leal L, González E, et al. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. *J Antimicrob Chemother*. 2017; 72(10): 2857–2861.
29. Leal L, León A, Torres B, et al. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. *J Antimicrob Chemother*. 2016; 71(7): 1987–1993.
30. Mayer KH, Jones D, Oldenburg C, et al. Optimal HIV post-exposure prophylaxis regimen completion with single tablet daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/ Emtricitabine compared with more frequent dosing regimens. *J Acquir Immune Defic Syndr*. 2017; 75(5): 535–539.
31. Mitchell H, Furegato M, Hughes G, Field N, Nardone A. What are the characteristics of, and clinical outcomes in men who have sex with men prescribed HIV postexposure prophylaxis following sexual exposure (PEPSE) at sexual health clinics in England? *Sex Transm Infect*. 2017; 93(3): 207–213.
32. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. *Clin Infect Dis*. 2005; 41(10): 1507–1513.
33. Beymer MR, Bolan RK, Flynn RP, et al. Uptake and repeat use of postexposure prophylaxis in a community-based clinic in Los Angeles, California. *AIDS Res Hum Retroviruses*. 2014; 30(9): 848–855.
34. Haidari GFS, Fox J, Fitzgerald J, et al. Acute HIV infection after initiation of post-exposure prophylaxis following sexual exposure: reasons, challenges and suggested management. *HIV Med*. 2015;16(Suppl. 2)(P35):23.
35. Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. *Lancet*. 2000; 355(9205): 722–723.
36. Evans B, Duggan W, Baker J, Ramsay M, Abiteboul D. Exposure of healthcare workers in England, Wales, and Northern Ireland to bloodborne viruses between July 1997 and June 2000: analysis of surveillance data. *BMJ*. 2001; 322(7283): 397–398.
37. Kahn J, Martin J, Roland M, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. *J Infect Dis*. 2001; 183(5): 707–714.
38. Bennett A, Wainwright E, Lord E, Oduru M, Duncan S. The impact of the 2011 post-exposure HIV prophylaxis following sexual exposure (PEPSE) guidelines: A regional retrospective audit across three genitourinary centres. *HIV Med*. 2014; 15: 146.
39. Spice B, Bhaduri S, Sivaram M. An audit of PEPSE in the West Midlands. *HIV Med*. 2014; 15: 131.
40. Parkash V, Garner A, Gupta N. Evaluation of PEPSE use in a district general hospital genitourinary medicine department. *HIV Med*. 2014; 15: 148.
41. Awosusi F, Mashal S, O'Connell R. A retrospective audit in a London HIV clinic, assessing the post-exposure prophylaxis for HIV following sexual exposure (PEPSE). *HIV Med*. 2014; 15: 39–40.
42. Rowley D, O'Bara R, Quinlan M, Clarke S. Twenty-eight days later: Audit of postexposure prophylaxis following sexual exposure (PEPSE) in a community sexual health clinic for men who have sex with men. *Int J STD AIDS*. 2013; 24: 9–10.
43. Janmohamed K, Bull L, Payne D, et al. Post exposure prophylaxis following possible exposure to HIV infection: An evaluation of 391 attendances at three central London sexual health clinics. *Sex Transm Infect*. 2012; 88: A16.
44. Day S, Mears A, Bond K, Kulasegaram R. Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidance. *Sex Transm Infect*. 2006; 82(3): 236–237.
45. HIV Drug Resistance Database. Available from: <http://www.hivrd.org.uk/hiv-drug-resistance-uk>
46. Brown AE, Nash S, Connor N, et al. Towards elimination of HIV transmission, AIDS and HIV-related deaths in the UK. *HIV Med*. 2018; 19(8): 505–512.
47. Bradley-Stewart A, Urcia C, MacLean A, Aitken C, Gunson R. HIV-1 integrase inhibitor resistance among treatment naive patients in the West of Scotland. *J Clin Virol*. 2017; 92: 7–10.
48. del Mar Pujades Rodríguez M, Obasi A, Mosha F, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. *AIDS*. 2002; 16 (3): 451–462.
49. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. *N Engl J Med*. 2016; 375(9): 830–839.
50. Rodger ABT, Cambiano V, Vernazza P, Estrada V, Van Lunzen J, editor. *HIV Transmission Risk Through Condomless Sex If HIV+ Partner on Suppressive ART: PARTNER study*. CROI; 2014.
51. Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. *Lancet HIV*. 2018; 5(8): e438–e447.
52. Grant RM, Wiley JA, Winkelstein W. Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. *J Infect Dis*. 1987; 156(1): 189–193.
53. Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, Winkelstein W Jr. Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984–1989. *J Acquir Immune Defic Syndr*. 1993; 6(3): 303–312.
54. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. *Am J Epidemiol*. 1999; 150(3): 306–311.
55. Mastro TD, Kitayaporn D. HIV type 1 transmission probabilities: estimates from epidemiological studies. *AIDS Res Hum Retroviruses*. 1998; 14 (Suppl 3): S223–S227.
56. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. *N Engl J Med*. 1997; 336(15): 1072–1078.
57. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. *Int J Epidemiol*. 2010; 39(4): 1048–1063.
58. DeGruttola V, Seage GR III, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male homosexual partners. *J Clin Epidemiol*. 1989; 42(9): 849–856.
59. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. *AIDS*. 2010; 24(6): 907–913.



60. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. *N Engl J Med*. 1994; 331(6): 341–346.
61. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet*. 2001; 357(9263): 1149–1153.
62. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. *Am J Epidemiol*. 1998; 148(1): 88–96.
63. Downs AM, De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1996; 11(4): 388–395.
64. Donnelly C, Leisenring W, Kanki P, Awerbuch T, Sandberg S. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal. *Bull Math Biol*. 1993; 55(4): 731–743.
65. Hayes RJ, Schulz KF, Plummer FA. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. *J Trop Med Hyg*. 1995; 98(1): 1–8.
66. Peterman TA, Stoneburner RL, Allen JR, Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. *JAMA*. 1988; 259(1): 55–58.
67. del Romero J, Marinovich B, Castilla J, et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. *AIDS*. 2002; 16(9): 1296–1297.
68. Kaplan EH. Modeling HIV infectivity: must sex acts be counted? *J Acquir Immune Defic Syndr*. 1990; 3(1): 55–61.
69. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. *Arch Intern Med*. 1993; 153(12): 1451–1458.
70. Centres for Disease Control. Case-control study of HIV seroconversion in healthcare workers after percutaneous exposure to HIV-infected blood France, United Kingdom and United States, January 1988–August 1994. *Morb Mortal Wkly Rep*. 1995; 44: 929.
71. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. *Am J Med*. 1997; 102(5B): 9–15.
72. Richman KM, Rickman LS. The potential for transmission of human immunodeficiency virus through human bites. *J Acquir Immune Defic Syndr*. 1993; 6(4): 402–406.
73. Wahn V, Kramer HH, Voit T, Bruster HT, Scrampical B, Scheid A. Horizontal transmission of HIV infection between two siblings. *Lancet*. 1986; 2(8508): 694.
74. Cresswell FV, Ellis J, Hartley J, Sabin CA, Orkin C, Churchill DR. A systematic review of risk of HIV transmission through biting or spitting: implications for policy. *HIV Med*. 2018; 19(8): 532–540.
75. Gray RH, Wawer MJ. Probability of heterosexual HIV-1 transmission per coital act in sub-Saharan Africa. *J Infect Dis*. 2012; 205(3): 351–352.
76. Rothenberg RB, Scarlett M, del Rio C, Reznik D, O'Daniels C. Oral transmission of HIV. *AIDS*. 1998; 12(16): 2095–2105.
77. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? *Sex Transm Dis*. 2001; 28(10): 579–597.
78. Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. *J Infect Dis*. 2018; 218(1): 16–25.
79. Sadiq ST, Taylor S, Kaye S, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. *AIDS*. 2002; 16(2): 219–225.
80. Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. *AIDS*. 2010; 24(17): 2733–2737.
81. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. *J Infect Dis*. 2002; 185(1): 45–52.
82. Public Health England. Guidance on management of potential exposure to blood-borne viruses in emergency workers, 2019.
83. Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task F. Guideline for hand hygiene in health-care settings: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force. *Infect Control Hosp Epidemiol*. 2002; 23(12 Suppl): S3–S40.
84. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. *AIDS*. 2006; 20(6): 805–812.
85. Sin WW, Lin AW, Chan KC, Wong KH. Management of health care workers following occupational exposure to hepatitis B, hepatitis C, and human immunodeficiency virus. *Hong Kong Med J*. 2016; 22(5): 472–477.
86. Nwaiwu CA, Egro FM, Smith S, Harper JD, Spiess AM. Seroconversion rate among health care workers exposed to HIV-contaminated body fluids: The University of Pittsburgh 13-year experience. *Am J Infect Control*. 2017; 45(8): 896–900.
87. Rajkumari N, Thanbuana BT, John NV, Gunjijal J, Mathur P, Misra MC. A prospective look at the burden of sharps injuries and splashes among trauma health care workers in developing countries: true picture or tip of iceberg. *Injury*. 2014; 45(9): 1470–1478.
88. Himmelreich H, Rabenau HF, Rindermann M, et al. The management of needlestick injuries. *Dtsch Arztebl Int*. 2013; 110(5): 61–67.
89. Gupta A, Anand S, Sastry J, et al. High risk for occupational exposure to HIV and utilization of post-exposure prophylaxis in a teaching hospital in Pune, India. *BMC Infect Dis*. 2008; 8: 142.
90. Thomas MG, Hopkins CJ, Luey CE. Transmission of HIV infection by severe bites. *Int J STD AIDS*. 2019; 30(9): 927–929.
91. Hagan H. Agent, host, and environment: hepatitis C virus in people who inject drugs. *J Infect Dis*. 2011; 204(12): 1819–1821.
92. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and

- prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Global Health*. 2017; 5(12): e1192–e1207.
93. Public Health England HPS, Public Health Wales, and Public Health Agency Northern Ireland. Unlinked Anonymous Monitoring (UAM) Survey of HIV and viral hepatitis among PWID. 2019.
  94. Nash S, Desai S, Croxford S et al. Progress towards ending the HIV epidemic in the United Kingdom: 2018 report. 2018 November, 2018.
  95. Public Health England HPS, Public Health Wales, and Public Health Agency Northern Ireland. Shooting Up: Infections among people who inject drugs in the UK, 2018. 2019.
  96. O'Halloran C, Sun S, Nash S et al. *HIV in the United Kingdom: Towards Zero 2030*. Public Health England; 2019.
  97. McAuley A, Palmateer NE, Goldberg DJ, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. *Lancet HIV*. 2019; 6(5): e315–e324.
  98. Edmundson C, Heinsbroek E, Glass R, et al. Sexualised drug use in the United Kingdom (UK): a review of the literature. *Int J Drug Policy*. 2018; 55: 131–148.
  99. Public Health England HPS. *Public Health Wales, and Public Health Agency Northern Ireland, Substance misuse services for men who have sex with men involved in chemsex*. Public Health England; 2015.
  100. Kennedy R, Murira J, Foster K, Heinsbroek E, Sinka K. *Sexualised Drug Use and Specialist Service Experience Among Men Who Have Sex With Men Attending Urban and Non-Urban Sexual Health Clinics in England and Scotland: Results of the Drugs and Sex Survey*. British Association of Sexual Health and HIV; 2018.
  101. Clutterbuck D, Asboe D, Barber T, et al. United Kingdom national guideline on the sexual health care of men who have sex with men. *Int J STD AIDS*. 2016; 2018: 956462417746897.
  102. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med*. 2000; 342(13): 921–929.
  103. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet*. 2010; 375(9731): 2092–2098.
  104. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS*. 2009; 23(11): 1397–1404.
  105. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV positive partner is using suppressive antiretroviral therapy. *JAMA*. 2016; 316(2): 171–181.
  106. Truong HM, Berrey MM, Shea T, Diem K, Corey L. Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. *J Acquir Immune Defic Syndr*. 2002; 29(3): 232–243.
  107. Wood LF, Chahroudi A, Chen HL, Jaspan HB, Sodora DL. The oral mucosa immune environment and oral transmission of HIV/SIV. *Immunol Rev*. 2013; 254(1): 34–53.
  108. Kim JC, Martin LJ, Denny L. Rape and HIV post-exposure prophylaxis: addressing the dual epidemics in South Africa. *Reprod Health Matters*. 2003; 11(22): 101–112.
  109. Platt L, Jolley E, Rhodes T, et al. Factors mediating HIV risk among female sex workers in Europe: a systematic review and ecological analysis. *BMJ Open*. 2013; 3(7): e002836.
  110. UNAIDS. The GAP report 2014. 2014.
  111. Makwana N, Riordan FA. Prospective study of community needlestick injuries. *Arch Dis Child*. 2005; 90(5): 523–524.
  112. Abdala N, Stephens PC, Griffith BP, Heimer R. Survival of HIV-1 in syringes. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1999; 20(1): 73–80.
  113. European AIDS Clinical Society. EACS Treatment Guidelines V7.1, 2014. Available from: <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>
  114. Department of Health and Human Services PoAGfAaA. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, 2014. Available from: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolesc entgl.pdf>
  115. Taylor S, Davies S. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. *Curr Opin HIV AIDS*. 2010; 5(4): 335–343.
  116. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med*. 2012; 367(5): 399–410.
  117. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010; 363(27): 2587–2599.
  118. McCormack SDD editor. Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD study. Conference of Retroviruses and Opportunistic Infections; 2015 February 23–26 2015; Seattle.
  119. Molina JMCC, Charreau I, Meyer L, Spire B, Pialoux G, et al., eds. On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. Conference on retroviruses and opportunistic infections; 2015 February 23–26 2015; Seattle, USA.
  120. Irvine C, Egan KJ, Shubber Z, Van Rompay KK, Beanland RL, Ford N. Efficacy of HIV postexposure prophylaxis: systematic review and meta-analysis of nonhuman primate studies. *Clin Infect Dis*. 2015; 60 (Suppl. 3): S165–S169.
  121. Ruane PCA, Post FA, Schembri G, Jessen H, Trottier B. Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis week 96 results. 17th European AIDS Conference; Basel 2019.
  122. Electronic Medicines Compendium. Truvada SPC. Available from: [https://www.medicines.org.uk/emc/product/3890#UNDESIRABLE\\_EFFECTS](https://www.medicines.org.uk/emc/product/3890#UNDESIRABLE_EFFECTS)
  123. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med*. 2008; 358(20): 2095–2106.
  124. Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. *Clin Infect Dis*. 2011; 53(8): 807–816.
  125. Lennox JL, Landovitz RJ, Ribaldo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med*. 2014; 161(7): 461–471.

126. Electronic Medicines Compendium. Summary of medicinal product characteristics. Dolutegravir. 2019. Available from: <https://www.medicines.org.uk/emc/product/10057/smpc>
127. Quah SP, McIntyre M, Wood A, Mc Mullan K, Rafferty P. Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure. *HIV Med.* 2021; 22(2): e5–e6.
128. McAllister J, Read P, McNulty A, Tong WWY, Ingersoll A, Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. *HIV Med.* 2014; 15(1): 13–22.
129. Annandale D, Richardson C, Fisher M, Richardson D. Raltegravir-based post-exposure prophylaxis (PEP): A safe, well-tolerated alternative regimen. *J Int AIDS Soc.* 2012; 15: 132.
130. Annandale D, Richardson C, Fisher M, Richardson D. Raltegravir: Alternative postexposure prophylaxis regimen? *Int J STD AIDS.* 2013; 24: 4.
131. LA Leal L, Torres B, Inciarte A, Lucero C, Mallolas J, eds. Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials. Conference on Retroviruses and Opportunistic Infections; 2015 23-26th February 2015; Seattle, USA.
132. McAllister JW, Towns JM, McNulty A, et al. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. *AIDS.* 2017; 31(9): 1291–1295.
133. Scrivener J, McOwan A, Griffiths T, Stuart D. Recreational drug use among genitourinary medicine attendees: implications for service delivery. *Int J STD AIDS.* 2013; 24: 37–38.
134. Fätkenheuer G, Jessen H, Stoehr A, et al. PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis. *HIV Med.* 2016; 17(6): 453–459.
135. Diaz-Brito V, León A, Knobel H, et al. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. *Antivir Ther.* 2012; 17(2): 337–346.
136. Fätkenheuer G, Jung N, Jessen H, et al. Darunavir(DRV)/r-Based PEP versus standard of care (SOC) – the randomized PEPDar study. *Topics Antiviral Med.* 2014;22(e-1):497.
137. Milinkovic PB, Arenas-Pinto A, Brima N et al. Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra® in combination with Truvada® for HIV post exposure prophylaxis (MiPEP Trial). European AIDS Clinical Society; Barcelona 2015.
138. Cooper D, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. *J Infect Dis.* 2010; 201(6): 803–813.
139. Frange P, Meyer L, Ghosn J, et al. Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection. *Clin Microbiol Infect.* 2013; 19(5): E252–E255.
140. Medicines Health Regulatory Authority. Domperidone: risks of cardiac side effects – indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use. *Drug Safety Update* 2014; 7(10): A1.
141. Electronic Medicines Compendium. Raltegravir Summary of Product Characteristics for Isentress. Available from: <http://www.medicines.org.uk/emc/medicine/20484/SPC/>
142. Saad M, Casado-Castillo F, Kelly P. Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient. *Medicine.* 2019; 98(17): e15149.
143. Electronic Medicines Compendium. SPC raltegravir. Available from: <https://www.medicines.org.uk/emc/medicine/20484>
144. University of Liverpool. HIV Drug Interactions. Available from: <https://www.hiv-druginteractions.org/>
145. James B, Whitney AIH, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. *Nature.* 2014: 1–4.
146. Expert Advisory Group of AIDS HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS (2008) 2008. Available from: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/203139/HIV\\_post-exposure\\_prophylaxis.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/203139/HIV_post-exposure_prophylaxis.pdf)
147. Ford N, Venter F, Irvine C, Beanland RL, Shubber Z. Starter packs versus full prescription of antiretroviral drugs for post-exposure prophylaxis: a systematic review. *Clin Infect Dis.* 2015; 60(Suppl 3): S182–S186.
148. O'Keeffe C, Nwokolo N, Whitlock G. Does dropping day 5 PEP follow-up affect other outcomes? *HIV Med.* 2014; 15: 124–125.
149. Greub G, Maziero A, Burgisser P, Telenti A, Francioli P. Spare post-exposure prophylaxis with round-the-clock HIV testing of the source patient. *AIDS.* 2001; 15(18): 2451–2452.
150. Greub G, Gallant S, Zurn P, et al. Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person. *AIDS.* 2002; 16(8): 1171–1176.
151. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. *J Acquir Immune Defic Syndr.* 2012; 59(4): 354–359.
152. Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. *J Antimicrob Chemother.* 2010; 65(3): 543–547.
153. Centers for Disease Control and Prevention. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. *MMWR.* 2013;62.
154. Gary Brook SB, Ranjababu Kulasegaram R, Torkington A, Mutimer D, Hodges E. United Kingdom National Guideline on the Management of the Viral 1 Hepatitis A, B & C 2015, 2015. Available from: <http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx>
155. Cresswell FV, Fisher M, Hughes DJ, Shaw SG, Homer G, Hassan-Ibrahim MO. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. *Clin Infect Dis.* 2015; 60(2): 263–266.
156. de Vrieze NHN, van Rooijen MS, van de Loeff MS, de Vries HJC. Additional gonorrhoea and Chlamydia Infections found with rapid follow-up screening in men who have sex with men with an indication for HIV postexposure prophylaxis. *Sex Transm Dis.* 2014; 41(8): 515–517.
157. Vrieze NHN, Rooijen M, Vries HJC. P3.139 early incubating gonorrhoea and chlamydia infections in MSM with an indication For HIV post exposure prophylaxis (PEP). *Sex Transm Infect.* 2013; 89(Suppl 1): A191.1–A191.

158. Farrugia Parsons B, Fisher K, Cordery D, Couldwell D. Counselling improves follow-up HIV testing at Week 6 for HIV postexposure prophylaxis recipients. *Sex Health*. 2013; 10(3): 288–289.
159. Bentz L, Enel P, Dunais B, et al. Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. *AIDS Care*. 2010; 22(12): 1509–1516.
160. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. *AIDS*. 2004; 18(5): 787–792.
161. Brady M, Rodger A, Asboe D, et al. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. *HIV Med*. 2019; 20(Suppl 2): s2–s80.
162. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. *J Acquir Immune Defic Syndr*. 2013; 64(1): 79–86.
163. Solomon MM, Schechter M, Liu AY, et al. The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B. *J Acquir Immune Defic Syndr*. 2016; 71(3): 281–286.
164. Fox J, Brady M, Alexander H, et al. Tenofovir disoproxil fumarate fails to prevent HIV acquisition or the establishment of a viral reservoir: two case reports. *Infect Dis Ther*. 2016; 5(1): 65–71.
165. Streeck H, Verheyen J, Storim J, et al. Pre-exposure prophylaxis failure with tenofovir disoproxil. *AIDS*. 2017; 31(1): 176–177.
166. Wong D, Littlejohn M, Edwards R, et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B. *Liver Int*. 2018; 38(10): 1760–1769.
167. Kuo M-T, Tseng P-L, Chou Y-P, et al. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. *J Gastroenterol Hepatol*. 2018; 33(10): 1766–1772.
168. Wang M, Bian Q, Zhu Y, et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. *Aliment Pharmacol Ther*. 2019; 49(2): 211–217.
169. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. *N Engl J Med*. 2018; 379(10): 979–981.
170. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. *N Engl J Med*. 2019; 381(9): 827–840.
171. Zash R. Update on neural tube defects with antiretroviral therapy exposure in the Tsepamo study, Botswana. AIDS 2020 Virtual; Virtual 2020.
172. al MMe. Periconceptual antiretroviral exposure and central nervous system (CNS) and neural tube birth defects – data from Antiretroviral Pregnancy Registry (APR). International AIDS Conference Mexico City, 2019.
173. Hodel EM, Marzolini C, Waitt C, Rakhmanina N. Pharmacokinetics, placental and breast milk transfer of antiretroviral drugs in pregnant and lactating women living with HIV. *Curr Pharm Des*. 2019; 25(5): 556–576.
174. McNamara PJ, Abbassi M. Neonatal exposure to drugs in breast milk. *Pharm Res*. 2004; 21 (4): 555–566.
175. Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. *J Antimicrob Chemother*. 2015; 70(7): 1928–1941.
176. Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DOLPHIN-1 study). *PLoS Medicine*. 2019; 16(9): e1002895.
177. Kobbe R, Schalkwijk S, Dunay G, et al. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. *AIDS*. 2016; 30(17): 2731–2733.
178. Mulligan N, Best BM, Wang J, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. *AIDS*. 2018; 32(6): 729–737.
179. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*. 2016; 387(10013): 53–60.
180. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Sci Transl Med*. 2012; 4(151): 151ra25.
181. Molina J-M, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. *N Engl J Med*. 2015; 373(23): 2237–2246.
182. Cottrell ML, Yang KH, Prince HMA, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. *J Infect Dis*. 2016; 214(1): 55–64.
183. Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). *AIDS Res Hum Retroviruses*. 2016; 32(1): 32–43.
184. Krishna R, Rizk ML, Larson P, Schulz V, Kesiosoglou F, Pop R. Single- and multiple-dose pharmacokinetics of once-daily formulations of raltegravir. *Clin Pharmacol Drug Dev*. 2018; 7(2): 196–206.
185. Electronic Medicines Compendium. Truvada Summary of Product Characteristics, 2015. Available from: <https://www.medicines.org.uk/emc/medicine/15826>
186. Jackson A, Moyle G, Watson V, et al. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. *J Acquir Immune Defic Syndr*. 2013; 62(3): 275–281.
187. Hawkins T, Veikley W, St. Claire RL, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. *J Acquir Immune Defic Syndr*. 2005; 39(4): 406–411.
188. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. *HIV Med*. 2014; 15(Suppl 1): 1–85.
189. Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. *PLoS One*. 2012; 7(8): e43754.
190. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who

- have sex with men in the United States. *J Acquir Immune Defic Syndr*. 2015; 68(3): 337–344.
191. Brady M, Rodger A, Asboe D, Cambiano V, Clutterbuck D, Desai M, Field N, Harbottle J, Jamal Z, McCormack S, Palfreeman A, Portman M, Quinn K, Tenant-Flowers M, Wilkins E, Young I. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. *HIV Med*. 2019; 20 (S2): s2–s80.
  192. NHS England. Specialised Services Circular - Pre-Exposure Prophylaxis (PrEP) to prevent HIV: clarification of commissioning position, 2015. Available from: <http://www.bashh.org/documents/SSC1516%20Position%20regarding%20PrEP%20April%202015.pdf>
  193. Roedling S, Reeves I, Copas AJ, et al. Changes in the provision of post-exposure prophylaxis for HIV after sexual exposure following introduction of guidelines and publicity campaigns. *Int J STD AIDS*. 2008; 19(4): 241–242.
  194. Nakagawa F, Miners A, Smith CJ, et al. Projected lifetime healthcare costs associated with HIV infection. *PLoS One*. 2015; 10(4): e0125018.
  195. Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. *J Antimicrob Chemother*. 2019; 74(6): 1670–1678.

## SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

**How to cite this article:** Cresswell F, Asanati K, Bhagani S, et al. UK guideline for the use of HIV post-exposure prophylaxis 2021. *HIV Med*. 2022;00:1–52. <https://doi.org/10.1111/hiv.13208>

## APPENDIX A

### Potential for drug–drug interactions

When prescribing PEP, it is essential to ensure that the potential for drug–drug interactions is considered, and therefore an accurate patient medication history should be reconciled. Clinicians are advised to liaise with an HIV specialist pharmacist and/or use the Liverpool Drug Interaction website (<http://www.hiv-druginteractions.org>) for this purpose. A medicines reconciliation including the use of over-the-counter, supermarket and recreational drugs must be undertaken.

### Drug–drug interactions with tenofovir/emtricitabine

Tenofovir disoproxil/emtricitabine has no significant drug–drug interactions, although caution should be applied when tenofovir disoproxil/emtricitabine is co-administered with other potentially nephrotoxic agents.

Enhanced renal monitoring may be warranted in this situation.

Descovy® (tenofovir alafenamide/emtricitabine) is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Medicinal products that strongly affect P-gp and BCRP activity (e.g. rifampicin, carbamazepine and phenobarbital) may lead to decreases in drug absorption and co-administration should be avoided. However, a drug interaction study showed that, when tenofovir alafenamide is co-administered with rifampicin, therapeutic intracellular concentrations of the active moiety of tenofovir (tenofovir diphosphate) are measurable, suggesting that the interaction is not clinically significant [195].

### Drug–drug interactions with raltegravir

*In vitro* studies indicate that raltegravir is not a substrate of cytochrome P450 (CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not induce CYP3A4 and does not inhibit P-glycoprotein-mediated transport. Based on these data, raltegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of these enzymes or P-glycoprotein.

Raltegravir binds to divalent cations such as iron, aluminium, magnesium and calcium and forms a complex at the level of the gastrointestinal tract which results in less raltegravir being absorbed. Drug–drug interaction studies with antacids containing divalent cations showed a more pronounced reduction in raltegravir minimum concentration ( $C_{min}$ ) when raltegravir was administered once daily compared to a twice-daily regimen. A similar effect for iron supplements cannot be excluded. Therefore, concomitant use of metal cation-containing antacids, iron supplements and multivitamins should ideally be avoided with once-daily raltegravir or should be separated by at least 4 h from twice-daily raltegravir 400 mg [144]. Switch to a non-cation-containing acid-reducing agent is recommended during INSTI-based PEP if clinically indicated and nonessential mineral supplements should be stopped.

Raltegravir is eliminated mainly by metabolism via a UGT1A1-mediated glucuronidation pathway. Given that raltegravir is metabolized primarily via UGT1A1, caution should be used when co-administering raltegravir with strong inducers of UGT1A1 (e.g. rifampicin). Rifampicin reduces plasma levels of raltegravir; the impact on the efficacy of raltegravir is unknown. However, if co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir can be considered in adults. The impact of other strong inducers of drug-metabolizing enzymes, such as phenytoin and phenobarbital, on UGT1A1 is unknown. Less potent inducers (e.g. efavirenz, nevirapine, etravirine, rifabutin, glucocorticoids, St John's wort and pioglitazone) may be used with the recommended dose of raltegravir.

Please seek advice from a specialist HIV pharmacist and/or use the Liverpool Drug Interaction website (<http://www.hiv-druginteractions.org>).

### **Drug–drug interactions with dolutegravir**

As dolutegravir is an alternative agent, detailed discussion of pharmacokinetics and drug–drug interactions is not included here. Like raltegravir, dolutegravir interacts with magnesium/aluminium-containing antacids. These should be taken well separated in time from the administration of dolutegravir. Other significant interactions include rifampicin and enzyme-inducing anti-epileptics; we advise use of the Liverpool Drug Interactions website to check interactions with all concomitant medication.

### **Drug–drug interactions with boosted regimens (protease inhibitors and Stribild/Genvoya)**

As these are alternatives for PEP, detailed discussion of pharmacokinetics and drug–drug interactions is not included here. Ritonavir and cobicistat are associated with numerous drug–drug interactions; for example, simvastatin and St John's Wort are contra-indicated with all boosted regimens. Co-administration of Stribild and some medicinal products that are primarily metabolized by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious and/or life-threatening reactions. Co-administration of ritonavir and medicinal products primarily metabolized by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse effects.

**APPENDIX B**  
**Post-exposure prophylaxis risk assessment proforma for use in emergency departments**

This checklist is an aid to clinical practice only and does not replace local expert advice where indicated. For further information, please refer to the BASHH PEP 2021 guideline.

<b>Section 1:</b>	
Date:.....Time:..... .....  Seen by (Name / Designation):	Patient Name:  DOB:  Address:
Date of Potential/Actual Exposure    .../...../.....    Time of exposure .....  Number of hours between exposure and consultation .....  <p style="text-align: center;"><u>Note: must be less than 72 hours since exposure to be eligible for PEP</u></p> Past Medical History: ..... ..... ..... .....  Medication History: (including over the counter / herbal remedies / multivitamins / recreational drugs ) ..... ..... ..... .....  Allergies: .....  Contraception:.....  Is the patient pregnant or at risk of pregnancy?.....  First day of Last Menstrual Period / cycle length (consider emergency contraception) ..... .....	
<p><b>Type of exposure (tick one)</b></p> <p><input type="checkbox"/> Occupational injury / Other Exposure, including injecting drug use (<b>proceed to section 2 on page 2</b>)</p> <p><input type="checkbox"/> Sexual Exposure (<b>proceed to section 3 on page 3</b>)</p>	

**Section 2: Occupational injury / Other Exposure**

Brief description of exposure:

.....  
.....  
.....  
.....  
.....

**Sharp instrument/needlestick:**  hollow needle  solid needle  BM stick lancet  Other:.....

Were gloves worn?  Yes  No Did needle pass through glove  Yes  No  Not known

**Splash injury:**  to eye/mouth  Splash to broken skin  Splash to intact skin

**Bite/Scratch**  Other (specify)..... Depth of injury: .....

**Material exposed to:**  Blood / Plasma  CSF  Saliva  Other (specify).....

**Was wound made to bleed immediately?**  Yes  No  Not known

**Was injury washed?**  Yes  No  Not known

**If unknown HIV status, has index partner / patient been consented and tested for BBV (HIV, Hep B/C)?**

Yes  No  Not known

Details:.....  
.....



**Section 3: Sexual Exposure**

Sexual Assault?  Yes  No

Has patient attended SARC:  Yes  No  
If not, please discuss (forensic examination and support)

Index partner details (the patients sexual contact): Male  Female  Trans


Ethnicity if known: .....

Duration of relationship: Regular  Ex-Regular  Casual

Type of sexual contact:

Any other relevant comments i.e injury/bleeding: (use diagram)

	Condoms		Ejaculation	
	Yes	No	Yes	No
Anal receptive	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anal insertive	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Vaginal receptive	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Vaginal insertive	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Oral	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



**Details of Index partner (the patient's sexual contact)**

Name/ Description:.....

DOB/Age:.....

Address/Area:.....

Tel number: .....

**Known Hepatitis B positive:**  Yes  No  Not known

**Known Hepatitis C positive:**  Yes  No  Not known

**HIV status**

- Definitely known HIV + (Status known to patient or HIV clinic)
- Probable HIV + (Patient told by contact or by someone else)
- Unknown HIV status

Is index partner / patient on antiretroviral treatment?  Yes  No  Not known / unsure

Does the index partner / patient have an undetectable viral load?  Yes  No  Not known / unsure

Index partner / patient HIV clinic location if known:.....

**Section 4: Summary table on PEP eligibility**

	Source HIV status			
	HIV positive		Unknown HIV status	
	HIV VL unknown / detectable	HIV VL undetectable	From high prevalence country / risk-group (e.g. MSM) <sup>a</sup>	From low prevalence country / group
<b>SEXUAL EXPOSURES</b>				
Receptive anal sex	Recommend	Not recommended <sup>b</sup>	Recommended	Not recommended
Insertive anal sex	Recommend	Not recommended <sup>b</sup>	Consider <sup>c,d</sup>	Not recommended
Receptive vaginal sex	Recommend	Not recommended <sup>b</sup>	Generally not recommended <sup>c,d</sup>	Not recommended
Insertive vaginal sex	Consider <sup>c</sup>	Not recommended	Generally not recommended <sup>c,d</sup>	Not recommended
Fellatio with ejaculation	Not recommended	Not recommended	Not recommended	Not recommended
Fellatio without ejaculation	Not recommended	Not recommended	Not recommended	Not recommended
Splash of semen into eye	Not recommended	Not recommended	Not recommended	Not recommended
Cunnilingus	Not recommended	Not recommended	Not recommended	Not recommended
<b>OCCUPATIONAL AND OTHER EXPOSURES</b>				
Sharing of injecting equipment	Recommended	Not recommended	Generally not recommended <sup>e</sup>	Not recommended
Sharps injury	Recommended	Not recommended	Generally not recommended <sup>c,f</sup>	Not recommended
Mucosal splash injury	Recommended	Not recommended	Generally not recommended <sup>c</sup>	Not recommended
Human bite	Generally not recommended <sup>g</sup>	Not recommended	Not recommended	Not recommended
Needlestick from a discarded needle in the community			Not recommended	Not recommended
Details of footnotes can be found in the full BASHH 2021 PEP guideline document online. <a href="https://www.bashh.org/guidelines">https://www.bashh.org/guidelines</a>				

**Section 5: Patient eligible for PEP? (decision to be based on table in appendix below)**

Yes, recommended     Not Recommended     Consider

We recommend provision of the full 28 day PEP course of where possible

PEP starter pack prescribed  )

**(See full guideline or seek URGENT specialist advice if any uncertainty or alternative regime required)**

Emergency contraception given  Yes  No Details.....

**Discussion points with the patient (Please tick)**

- The need for baseline bloods (including HIV test)
- Antiretrovirals are unlicensed for PEP
- Lack of conclusive data for PEP efficacy
- Importance of adherence to optimise efficacy
- Start PEP as soon as possible to maximise efficacy
- Advised too late if commenced after 72 hours
- Length of PEP is 28 days
- Drug side effects discussed
- Drug interactions including multivitamins, iron, antacids (advised to avoid whilst on PEP PEP)
- Seek urgent attention if symptoms of seroconversion (flu-like symptoms / rash)
- Advise condoms until final HIV test (in 10.5 weeks)
- Emergency contraception given (if applicable)
- Hepatitis B vaccine advised (if unsure if immune or in cases of sexual assault)
- Given PEP leaflet (patient leaflet from BASHH website)
- If given a starter pack (rather than the full 28 day course), advised of the need for urgent follow-up before the starter pack runs out to receive the rest of the course
- For occupational exposures: advised urgent follow up with occupational health ASAP and no later than within 72 hours

**Baseline tests to be obtained by Accident and Emergency clinician**

Tests	Taken		Taken		Taken		Taken
HIV		Hep B core antibody*		Hepatitis C antibody		LFT (ALT)	
Hepatitis B surface Antigen*		Hepatitis B surface antibody*		Creatinine and eGFR		Pregnancy test (if applicable)	

\*If the attendee has completed the hepatitis B vaccination course and has documentation of HepBsAb ≥10 IU at any time they are deemed a vaccine responder. If they are immunocompetent (e.g. HIV-negative) they do not require any further hepatitis B testing or follow up

## APPENDIX C

### Levels and grading of evidence

Strength of recommendation	Grading of evidence
<p>1. Strong recommendation</p> <p>For patients – most people in this situation would want the recommended course of action and only a small proportion would not.</p> <p>For clinicians – most people should receive the intervention.</p>	<p>A. High-quality evidence</p> <p>Benefits clearly outweigh the risk and burdens or vice versa.</p> <p>Consistent evidence from well-performed randomized controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit or risk.</p>
<p>2. Weak recommendation</p> <p>For patients – most people in this situation would want the suggested course of action, but many would not.</p> <p>For clinicians – examine the evidence or a summary of the evidence yourself and be prepared to discuss that evidence with patients, as well as their values and preferences.</p>	<p>B. Moderate-quality evidence</p> <p>Benefits clearly outweigh risk and burdens or vice versa.</p> <p>Evidence from randomized controlled trials with moderate limitations (inconsistent results, methodological flaws, indirect or imprecise results) or very strong evidence from some other research design. Further research may impact on our confidence in the estimate of benefit or risk.</p> <p>C. Low-quality evidence</p> <p>Benefits appear to outweigh the risk and burdens or vice versa.</p> <p>Evidence from observational studies, unsystematic clinical experience or randomized controlled trials with serious flaws. Any estimate of effect is uncertain.</p> <p>D. Very low-quality evidence</p> <p>Benefits appear to outweigh the risk and burdens or vice versa.</p> <p>Evidence limited to case studies.</p> <p>Good practice point (GPP)</p> <p>Recommended best practice based on the experience of the guideline working group.</p>

## APPENDIX D

### Summary of product characteristics (SPC) advice relating to pregnancy

Antiretroviral	SPC advice relating to pregnancy
<b>Tenofovir disoproxil/emtricitabine (TDF/FTC)</b>	The use of tenofovir disoproxil/emtricitabine may be considered during pregnancy, if necessary.
<b>Tenofovir alafenamide/ emtricitabine (TAF/FTC)</b>	Should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
<b>Zidovudine/lamivudine (ZDV/3TC)</b>	A large amount of data on pregnant women taking lamivudine or zidovudine indicate no malformative toxicity.
<b>Dolutegravir (DTG)</b>	In view of the potential risk (~0.3%) of neural tube defects, dolutegravir should not be used during the first trimester unless there is no alternative (see text for a more detailed explanation).
<b>Raltegravir (RAL)</b>	Raltegravir 400 mg twice daily should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus. There are no data for the use of raltegravir 1200 mg once daily in pregnant women so it is not recommended during pregnancy.
<b>Darunavir/ritonavir (DRV/r)</b>	Darunavir should be used during pregnancy only if the potential benefit justifies the potential risk.
<b>Elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine (EVG/COBI/TDF/FTC)</b>	In view of the lower concentrations of EVG and COBI in the second and third trimesters of pregnancy, neither should be initiated in pregnancy. It is the view of the writing group that EVG/COBI/TDF/FTC can be used for PEP during the first trimester of pregnancy if it is deemed the most clinically appropriate choice.